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CHAPTER 1: INTRODUCTION
Portions of the text and figures in this chapter were reprinted or adapted with permission from:
Siriwardena, S. U.; Chen, K.; Bhagwat, A. S., Functions and Malfunctions of Mammalian DNACytosine Deaminases. Chem Rev 2016, 116 (20), 12688-12710.
Copyright 2016, American Chemical Society
Activation-induced deaminase (AID) and apolipoprotein B mRNA-editing catalytic
polypeptide-like (APOBEC) proteins are found in all tetrapods, including primates and bony
fish. Primates appear to have the highest number of this family of proteins(1), and in humans
they include AID, APOBEC1, APOBEC2, seven APOBEC3 subfamily members (APOBEC3A,
APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H) and
APOBEC4(2)(Figure 1.1A). They deaminate cytosine to uracil in single-stranded DNA
(ssDNA)(3-8), or in both ssDNA and RNA(7,9-11) (Figure 1.1B).
A

B

Figure 1.1. Structure and function of human AID/APOBEC proteins. (A) Bar diagrams of
aligned human AID/APOBEC proteins. The zinc-dependent cytidine deaminase domain (ZDD)
motifs (black) and number of amino acids are indicated. Figure adapted from reference (12) with
permission from copyright clearance center. (B) AID/APOBEC mediated cytosine deamination
in ssDNA generates uracil.
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These enzymes are part of the cellular innate and adaptive immune response that protects
the host organism against infection. The important immunological functions of these enzymes
come with the potential risk of causing considerable damage to the host genome. Understanding
the structural organization, biochemical properties and functions of these enzymes help broaden
the knowledge about their mutagenic consequences.
1.1 Biochemical properties of AID/APOBEC proteins
AID/APOBEC proteins have a characteristic zinc-coordination motif (H-X-E-X23-28-P–
C-X-C) within the active site where a water molecule binds Zn2+ and the metal ion is coordinated
by one histidine and two cysteines(13). While the genes for AID, APOBEC1 (A1), APOBEC3A
(A3A), APOBEC3C (A3C) and APOBEC3H (A3H) contain a single Zn2+-binding domain,
genes for APOBEC3B (A3B), APOBEC3D (A3D), APOBEC3F (A3F) and APOBEC3G (A3G)
have resulted from duplications of the primordial gene(1,14) and contain two putative zincbinding motifs. In all cases where there are two Zn2+-binding domains, only the carboxy-terminal
domain is catalytically active. Based on prior work with bacterial and yeast cytidine deaminases,
it has been suggested that a conserved glutamate plays a central role in catalysis by shuttling a
proton between the bound water molecule and N3 of cytosine, and between the resulting OH- and
the exocyclic amino group of cytosine(13). These enzymes show little activity towards the free
cytosine base, its nucleosides or mononucleotides(3,6).
Different AID/APOBEC proteins deaminate cytosines in different preferred sequence
contexts. They have a stronger preference for specific bases on the 5’ side of the target cytosine
than on its 3’ side. While AID prefers WRC(15) (W is A or T, R is purine, target cytosine is
underlined) sequence, A3G prefers CCC, and the other family members target YC sequences (Y
is pyrimidine) with a preference for T as the pyrimidine(3,16).
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Sequence-specific

DNA-binding

enzymes

use

multiple

“facilitated”

diffusion

mechanisms to speed up target site search. These mechanisms include sliding along DNA,
microscopic dissociation-reassociation events between closely spaced sites and intersegment
transfer(17). These mechanisms aid processive action of the enzymes on multiple closely spaced
targets on DNA. In contrast, if an enzyme undergoes macroscopic dissociation from DNA
(becomes part of the bulk solvent) after one turnover, it is considered to be non-processive or
distributive. It should be noted that the AID/APOBEC enzymes are likely to be parts of multiprotein complexes and their association with other proteins may alter their diffusional behavior.
Regardless, processivity of several members of the AID/APOBEC family members on ssDNA
has been reported and the results have implications to the finding that mutations associated with
AID or APOBEC3s are often clustered.
Purified AID processively scans ssDNA and introduces clusters of deaminations in
ssDNA, and this may explain the frequent clustering of mutations created by this enzyme in the
immunoglobulin genes(15,18). Some of the APOBECs may also act in a processive manner, but
this is somewhat controversial. Several studies suggest that A3G is also a processive
enzyme(19), but at least one article argues that it does not efficiently deaminate closely spaced
cytosines and moves between successive targets predominantly through intersegmental transfer.
Similar to A3G, A3F also acts processively but exhibits two distinct ssDNA scanning
mechanisms. A3A has been reported to be processive (20) or non-processive (21,22) in different
studies.
APOBEC2 was the first member of the family for which the crystal structure became
available(23) and subsequently the structures of several APOBEC3 subfamily proteins have been
determined. The structures have been determined for A3A(24-27), A3C(28) and the C-terminal
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catalytic domains of A3B and A3F(29-31). Additionally, several structures of the C-terminal
domain of A3G (A3G-CTD)(32-35) and one structure of the N-terminal Vif-binding domain
have been reported based on X-ray crystallographic and NMR studies. Until recently, the crystal
structure for AID was elusive and hence it was modeled based on APOBEC structures in order to
understand the relationship between its active site structure and catalytic activity(36). However,
the crystal structure of the human AID has now become available and it confirms that AID is
structurally quite similar to the APOBEC proteins(37). Structures of both the N-terminal and Cterminal domains of A3G have been separately reported(25,34,35), but the complete structure of
a two Zn2+-domain member of the APOBEC3 subfamily has not been reported. Recently, the
crystal structures of A3A and a chimera of A3A and C-terminal domain of A3B with bound
DNA were also reported(26,27). They reveal that a U-shaped DNA confirmation is allowing
target cytosine to be inserted into the active site pocket. A flipped out -1 thymine makes a direct
contact with the protein, which explains the strong 5'-TC preference. Together these findings
provide insight into the unique properties among APOBEC family members, but the fact that
many of the proteins were mutated to make them more soluble, limit our understanding of the
structures and DNA binding of these proteins.
ENDscript 2 software(38) was used to compare representative APOBEC3 subfamily
structures and identify their common structural elements (Figure 1.2). The proteins share
extensive secondary structural similarity reflecting their sequence similarities and their tertiary
structure has a central  sheet surrounded by three helices on each side. The principal difference
between the different structures is that while A3A, A3C and A3F have a continuous β2 strand,
this strand is interrupted by an  helix or a  turn in A3B and A3G structures (Figure 1.2).
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Figure 1.2. Multiple sequence alignment of human APOBEC3 proteins with known crystal
structures. ENDscript 2 software was used to generate the sequence alignment of A3A (PDB:
4XX0), A3B-CTD (PDB: 5CQD), A3C (PDB: 3VM8) and A3G-CTD (PDB: 3IR2) using A3FCTD (PDB: 4IOU) as the query. It is important to note that some of the crystallized proteins had
several amino acid substitutions and in cases of proteins with two Zn2+ binding domains, only the
carboxy-terminal domain (CTD) was crystallized. Residues shown in white against a red
background are identical and similar residues are shown in red against a yellow background. The
amino acid residues that constitute the active site are marked with red asterisks and the putative
DNA binding region is identified with a dashed red line. Secondary structure elements in all
APOBEC3 crystal structures are displayed above the sequence alignment (α helices with
squiggles, β strands with arrows and turns with the letter T). Helices are numbered from α1
through α6, strands from β1 through β5 and loop regions from L1 through L10.
The biochemical consequences of this difference are unclear. The active site Zn2+ is
coordinated by one His and two Cys residues and these residues are at the edges of two helices
that lie close to the surface of the protein (Figures 1.2 and 1.3). The coulombic surface potential
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map of A3F-CTD(39) shows that the catalytic center is near a cavity with negative potential and
this is likely to be the pocket in which the target cytosine is inserted. There is no groove with a
strong positive potential on the protein surface near the catalytic center for nucleic acid binding.
Instead, there is a surface patch of neutral/positive potential that extends from the catalytic
residues towards loop 7 and this may interact with the substrate DNA (Figure 1.3).

Figure 1.3. Surface potential and possible DNA binding regions in APOBEC3F. The
Coulombic surface potential of the A3F-CTD structure was generated using UCSF Chimera
software. The color code is blue (positive), white (neutral) and red (negative). C280, C283 and
H249 residues coordinate Zn ion (magenta). Active site glutamate (E251) is also shown. L7
(yellow) is the putative DNA sequence recognition loop and two possible trajectories for DNA
binding are shown as dashed green lines.
A number of independent lines of evidence show that the principal determinant of DNA
sequence specificity within the AID/APOBEC proteins is the loop 7 (Figure 1.3). This
conclusion is supported by experiments in which loop 7 was exchanged between different
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members of the family resulting in the swapping of sequence specificities(40-42). Additionally,
replacement of loop 7 in AID with the corresponding sequence in A3A resulted in increased
preference for methylated cytosines for deamination that is characteristic of A3A(10). Molecular
docking of a single-stranded DNA template with A3A also suggested interaction between several
residues in loop 7 with DNA, with additional interactions with loops 1, 3 and 5(43). Alanine
scanning mutagenesis of loop 7 in AID revealed several residues essential for deamination
activity(44). Saturation mutagenesis of loop 7 residues in AID followed by multiple rounds of
genetic selection for cytosine deamination confirmed this result(44). In other experiments, D317
in this loop of A3G was substituted with tyrosine resulting in the changing of the sequencespecificity of the enzyme from 5’-CC to 5’-YC(45). Mutational studies of A3F also showed that
a replacement of W310 in this loop with alanine resulted in decreased binding to DNA and
reduced deaminase activity(46). NMR studies of interactions between free deoxyribonucleotides
and crystal structures of ssDNA with A3A showed that residues in the loops 1, 3, 5 and 7 interact
with nucleotides on either side of the target cytosine(24,26,27)(Figure 1.4). Together these
studies show that while loop 7 is the principal determinant of sequence specificity in
AID/APOBEC enzymes, loops 1, 3 and 5 also contribute to DNA binding(21,26,27,40,47).
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Figure 1.4. DNA binding at the active site of A3A. The protein is presented as a green-colored
ribbon diagram and the bound DNA is in stick representation. A zinc ion at the active centre is
depicted as a magenta-colored sphere. Figure adapted from reference (27) with permission from
copyright clearance center.
Despite extensive studies, the subunit composition of these enzymes is poorly understood
and remains controversial. The multimerization of these proteins in vitro has been studied using
a large number of biochemical and biophysical techniques including co-immunoprecipitation,
yeast two-hybrid analysis, bimolecular fluorescence complementation, size exclusion
chromatography, matrix-assisted laser desorption ionization time-of-flight spectrometry, small
angle X-ray scattering, X-ray crystallography, nuclear magnetic resonance, density gradient
separation of cytoplasmic components, atomic force microscopy as well as through studies of
live and fixed cells(19,24,29,48-57). Based on such studies a variety of different subunit
compositions have been reported for most of the proteins. A3G has been studied most
extensively in this regard and the data collectively suggest that A3G can be present as a
monomer, dimer, tetramer or an oligomer. The process of oligomerization may depend on
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protein modifications, intracellular protein concentration(49), salt conditions(58), presence of
RNA(53,59), presence of HIV-1 viral infectivity factor, Vif (see below)(60,61), subcellular
localization(54,62) and the cell type in which it is expressed. This makes it difficult to correlate
multimerization of these proteins with their biological function.
A1 is known to cause C to U conversion in mRNA(9), but it can also act on cytosines in
ssDNA(63). The RNA editing by A1 in the mammalian apolipoprotein B gene creates a
termination codon that shortens the resulting protein with altered function(64). The function of
its DNA editing ability is not known. AID is required for the creation of high affinity antibodies
against antigens. It causes mutations in the immunoglobulin (Ig) genes and facilitates
“maturation” of antibodies following an infection(65). The biological function of APOBEC3
subfamily proteins is to introduce mutations in the genome of viruses infecting cells and within
endogenous retroelements during their retrotransposition(66,67). APOBEC2 and APOBEC4 will
not be discussed further because they do not show any deaminase activity and their functions
remain poorly defined(63).
1.2 Activation-induced deaminase (AID)
The biological function of AID in adaptive immunity is well understood, but the
biochemical pathways it participates in remain poorly understood at the molecular level. In
particular, the steps downstream of AID action on DNA do not fit our understanding of DNA
repair pathways and it appears that AID colludes with DNA repair pathways to rearrange the
genomes of B lymphocytes and alter their genetic information. It is a major challenge to
understand how the enzymes in base-excision repair (BER) and mismatch repair (MMR) cause
high levels of mutations and strand breaks with the help of AID, when several decades of studies
have shown that these pathways have evolved to protect the genome. Finally, it would be naïve
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to think that the damage done by AID to the genome can be restricted to the Ig loci. Increasingly,
it is becoming clear that cytosines outside the Ig genes are targets of AID and that this is a source
of mutations and genome instability in B lymphocytes and other cells.
1.2.1 Somatic hypermutation
The maturation of antibodies occurs in B cells when they enter transient structures called
germinal centers that form within peripheral lymphoid organs. AID causes hypermutations in the
“variable region” of antibody genes, resulting in an increase in the affinity of antibodies for
antigens. This process is called somatic hypermutation (SHM). During their maturation process,
the antibodies are transported to the surface of B lymphocytes and act as receptors for antigens.
The ability of these B cell receptors to bind an antigen and interact with follicular helper T cells
assures their survival and proliferation. This is called clonal selection(68-70) and repeated
cycling of B cells through a process of hypermutation and selection is responsible for a timedependent increase in the affinity of antibodies for antigens derived from an infectious agent(7173).
Prior to an infection, combinatorial reassortment of variable (V), diversity (D) and
junction (J) segments generates millions of unique combinations in different cells and creates the
V(D)J exons in the Ig genes. The vertebrate B lymphocytes acquire hypermutations in a region
that includes the V(D)J exon either through a process that involves damage to DNA followed by
error-prone repair (SHM; Figure 1.5) or gene conversion (GC) between V(D)J and upstream
pseudo-V segments(74). AID is required for both these processes(63,65,75). GC of Ig genes is
not observed in humans and will not be discussed here.

11

Figure 1.5. Role of AID in antibody maturation. Schematic organization of the murine heavy
chain gene (IgH) and its alterations during antibody maturation are shown. Abbreviations- VDJRearranged V, D and J segments; E, enhancer, S, switch region; C, constant region; 3'-RR,
regulatory region, Pol II, RNA polymerase II; AID, activation induced deaminase; UNG2,
nuclear form of UNG; AP endonuclease, abasic endonuclease; MMR, mismatch repair; TLS
polymerase, translesion synthesis polymerase; NHEJ, non-homologous end-joining; altEJ,
alternate end-joining. The subscripts μ, ε and α to different constant segments. Representative
base substitution mutations within VDJ (SHM) and the μ-ε hybrid switch region are shown and
the IgM to IgE isotype switch in the antibody is indicated in the figure.
During SHM, mutations are introduced in the variable regions of the Ig genes starting
about 150 bp downstream of the Ig promoters and ending in the intron separating V(D)J from the
constant domain exons (Figure 1.5). The mutations caused by AID include all transitions and
transversions, and generally occur at a rate of about 10-3 per bp per generation. About 30% of the
mutations are found in the two hotspots 5’-RGYW/5’-WRCY (W is A or T, R is purine and Y is
pyrimidine) and TTA/TAA(76) and show a roughly bell-shaped distribution over the region.
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There is no detectable strand bias in the mutations, suggesting that the mutational process acts on
both the template and the coding strand of the gene.
As the sequence selectivity of purified AID is WRC(15), and hence the principal hotspot
for SHM, RGYW/WRCY(77), may be solely determined by this selectivity. However, a copying
of uracils generated by AID results in only C:G to T:A transitions and other types of base
substitutions found in SHM are caused by translesion synthesis (TLS) polymerases. In this
model(78), error-prone repair of uracils results in the creation of any of the three possible base
substitutions (Figure 1.6). UNG2 excises the uracil creating an abasic (a.k.a. AP) site and a TLS
polymerase inserts any one of the four bases across the AP site. TLS polymerase  would
predominantly insert an adenine across the AP site causing a C:G to T:A mutation(79), but other
TLS polymerases may insert other bases across the AP site expanding the spectrum of mutations.
For example, REV1 inserts C across an AP site(80,81) and would create C:G to G:C
transversions. This model further suggests that the actions of MMR and UNG2 help extend the
mutations to the base pairs flanking the target cytosine(78,82,83), but the mechanistic details of
this process are unclear. Together, these processes spread the mutations outside the WRC sites
that are the targets of AID for deamination and allow the creation of all six base substitution
mutations. The roles of TLS polymerases Pol and REV1 in shaping the mutation spectrum in
SHM has been reviewed in greater detail elsewhere(84-86).
SHM requires transcription of the target sequences(87,88) and this topic was reviewed
recently(89) There are good biochemical reasons why AID is likely to act at transcription pause
or arrest sites. Transcription causes separation of DNA strands potentially exposing them to AID.
However, AID is a slow enzyme (rate of deamination of 0.03 sec-1)(18,90,91), and hence cannot
capture cytosines in a transcription bubble that normally stays open for about 0.1 sec during
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normal elongation(92). Thus, AID is much more likely to find cytosines in ssDNA at a pause or
arrest site than within a transcript elongation complex(93).

Figure 1.6. Consequences of cytosine deamination in a transcription bubble. The direction
of transcription is shown by an arrow and the mRNA is shown in green. During transcription the
cytosines in the non-template strand of the transcription bubble are accessible and may be
deaminated by the AID/APOBEC proteins. The resulting uracils may be repaired through errorfree base excision repair restoring the C:G pair, copied during replication creating G:C to A:T
mutations or undergo error-prone repair resulting in all possible base substitutions. N: any base,
N': complement of N.
Many structural and mechanistic aspects of the interaction between AID and the
transcription bubble are poorly understood. For example, the structure of the transcript
elongation complex shows that the non-template strand within the transcription bubble is more
accessible than the template strand(94) (Figure 1.6). However, there is no deamination bias in
favor of the non-template strand during SHM(82,83). An attractive model that overcomes this
problem proposes that the RNA in the transcription bubble is removed by a ribonuclease
exposing the template strand(95-97). However, it is unclear as to how the ribonuclease accesses
3’ end of the nascent pre-mRNA for degradation. The RNA is paired with the template strand
and lies deep within the RNA polymerase (RNAP). Also, the forces that keep the two DNA
strands apart after the degradation of RNA and removal of the polymerase from the DNA have
not been described. Furthermore, if AID acts at transcription pause sites, it is not clear whether
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the pauses occur randomly along the DNA or are caused by specific events such as formation of
secondary structure(98,99) or the creation of DNA supercoiling domains(100). Another
possibility is that two convergent elongating polymerases collide within the V(D)J segment
causing transcription arrest and creating a region of single-strandedness(101). Interestingly, a
single-molecule study showed that AID can cause T7 RNAP elongation complexes to stall(102),
eliminating the need for other protein or structural factors to promote transcriptional pausing or
stalling. This is similar to the original model for how AID may work(87) and underlines the need
for an in vitro coupled transcription/deamination experimental model for answering many of the
mechanistic questions about AID biochemistry.
Early work on AID did not provide direct experimental evidence that AID causes
cytosine deaminations in the B cell genome. The role of AID in SHM was judged solely through
genetics (loss of SHM in AID-/- mice, ref.(65)) or by determining mutation spectra in mice
deficient in the repair of uracils(103) (UNG-/-) and/or base-base mismatches(82,83,104) (MSH2-/or MSH6-/-). More recent studies provide more direct evidence for the creation of uracils by
AID(105-107).
When DNA from splenocytes of immunized UNG-/- mice was sequentially treated with
Escherichia coli Ung and an AP endonuclease to generate strand breaks, the breaks were found
to occur in both the variable and the switch regions(105). This study showed that uracils were
present in both the DNA strands of the switch region and estimated that there are about 0.8
uracils/103 bp in the S region of activated B cells(105). This number is several orders of
magnitude higher than the number of uracils found in monocytes from un-immunized mice(108),
but may not be sufficient to explain the double-strand breaks (DBSs) promoted by AID (see
below).
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In a different study, uracils in DNA were replaced with biotin-containing tags, and total
genomic uracils were quantified following ex vivo stimulation of WT and UNG-/splenocytes(107). According to this study, the genomic uracil levels in UNG-/- splenocytes
increased about ten-fold in the first three days following stimulation, and this paralleled the
increase in AID gene expression and nuclear DNA-cytosine deamination activity. The study
estimated that the total number of uracils in the genome of UNG-/- B cells was at least a few
thousand(107), which is larger than what can be accounted for by the excess uracils in the Ig
genes detected by the strand cleavage assay described above(105). This suggests that during the
activation of B cells a large number of uracils are introduced in the genome, and most of the
uracils lie outside the Ig genes.
When WT splenocytes were stimulated, UNG2 (the nuclear form of UNG) expression
and nuclear uracil excision activity increased commensurately with the increase in AID
expression and, in contrast to UNG-/- splenocytes, no net increase in genomic uracils was
detected. The lack of increase in the uracil content was also seen in genomes of stimulated
human tonsillar cells(107). Hence, within the limits of detection of this assay, generation of
genomic uracils and their removal are balanced during normal B cell maturation.
Although this study found that most uracils created by AID must lie outside Ig genes, it is
unclear whether these uracils were in U:A or U•G pairs. The study used E. coli Ung to excise the
uracils(107) and this enzyme excises uracils from both U•G and U:A pairs. Hence it is possible
that some of the detected uracils resulted from the insertion of dU by DNA polymerases across
from dA. Such incorporations of uracils in DNA have no mutagenic consequences. Mutations
caused by AID in non-Ig genes are discussed below in the section 1.2.4.

16
1.2.2 Class-switch recombination
Following an infection, mammalian B cells undergo an additional genetic alteration,
class-switch recombination(109,110) (CSR). It is a region-specific recombination process that
replaces constant heavy chain of immunoglobulins, , with one of the other chains (Figure 1.5).
This creates antibodies of different isotypes that interact with different cellular receptors to
perform distinct immune functions. AID is essential for CSR(65).
AID promotes the formation of DSBs in the two switch regions(111) that participate in
recombination that occurs during CSR. The non-homologous end-joining or the alternate endjoining process connects the two broken ends replacing the  constant segment with one of the
downstream constant segments(110) (Figure 1.5). The critical unanswered question regarding
this process is how AID promotes the formation of DSBs. CSR is almost completely eliminated
in UNG-/- mice(103) and inactivation of MMR proteins MSH2 or MSH6 also reduces efficiency
of CSR(112,113) leading to the proposal that BER and MMR cooperate to generate the DSBs
needed for CSR(109,110).
A possible way in which AID may promote the formation of DSBs is if the repair of U•G
mispairs stops after hydrolysis of the AP sites by the AP endonuclease APE1. If this incomplete
BER reaction pathway were to process two closely spaced U•G mispairs containing uracils in
opposite strands during a short time interval, a DSB would be created. Although, APE1 does
appear to be required for CSR(114), it is unclear how the subsequent steps in canonical BER are
prevented from taking place during CSR. It is also unclear why this incomplete BER does not
occur over the whole B cell genome. If incomplete BER were to happen on a genome-wide scale,
potentially lethal strand breaks would be created during the repair of about 15,000 AP sites that
are created in every cell during every generation through depurination(115). An additional
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problem with this pathway for generating DSBs is that the number of uracils in the S regions
detected by Maul et al.(105) is not large enough to create closely spaced U•G mispairs.
Therefore, either the number of uracils generated by AID in the S regions is underestimated by
Maul et al.(105) or AID creates closely spaced uracils on opposite strands in a concerted fashion
in the fraction of cells undergoing CSR (which is generally <<50%). AID processively
deaminates cytosines in ssDNA generating multiple clustered mutations in this strand(15), but
simultaneous creation of mutations on both DNA strands by AID has not been demonstrated.
Therefore, a great deal of additional work is needed to validate this model for CSR.
The dependence of efficient CSR on MMR may be explained by the binding of the
MutS (MSH2•MSH6) complex to other U•G mispairs in the S regions. One problem with this
hypothesis is that the MMR is normally coordinated with DNA replication in the S phase to
correct replication errors and CSR occurs mainly in the G1 phase. A possible answer to this
problem may lie in a recently described non-canonical replication-independent mismatch repair
(ncMMR) pathway in extracts of B cell tumor lines(116,117). In this process, binding of MutS
to U•G is followed by random nicking of DNA by the MutL complex. Exonuclease 1 resects
the DNA from these nicks and creates DSBs(117). Regardless of the molecular details of how
DSBs are created, it is unclear at this time whether U•G mispairs created by AID outside the Ig
genes are also subject to ncMMR creating DSBs. Strand breaks outside the Ig genes have been
detected during B cell stimulation(118) and it is possible that they are the result of incomplete
BER or ncMMR of uracils created by AID outside Ig genes.
During CSR, mutations are also introduced in the two switch (S) regions in which DSBs
are created (Figure 1.5). The switch regions contain pentameric repeats with sequences such as
GGGGT and GAGCT, and a majority of switch junctions lie at these repeats(119). Deletions and
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base substitutions are frequently found near such junctions. The spectrum and distribution of
substitution mutations in the switch regions are not as well-documented as V(D)J mutations, but
they also have a preference for RGYW/WRCY targets(120), extend over several thousand base
pairs and do not show a strand preference(121). However, no biological function has been
attributed to these mutations and they appear to be the result of a sloppy process of generating
strand breaks. Consistent with this hypothesis, analysis of sequences of S switch regions has
shown that AID creates mutations in this region even without isotype switching(120).
1.2.3 DNA demethylation
The original suggestion that AID may play a role in DNA demethylation was based on
the observation that 5-methylcytosines (5mC) in DNA is a substrate for AID(122). It was
postulated that the T•G mispairs resulting from the deamination of 5mC could be repaired
through base excision repair pathway restoring a C:G pair(123,124). Furthermore, detection of
AID gene expression in oocytes and embryonic stem cells(122) was considered suggestive of
AID’s role in the erasure of DNA methylation during early stages of mammalian embryogenesis
and stem cell development. However, AID was not found in testis(122,125), and genetic and
biochemical studies of purified AID showed that 5mC is a poor substrate for AID(4,10,126-128).
Subsequent discovery of the ten-eleven translocation (TET) family enzymes which convert 5mC
in DNA to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC)(129,130) and the detection of these modified bases in the genomes derived from both the
parents within early embryos (reviewed in reference(131)) makes it unlikely that AID plays a
major role in genome-wide DNA demethylation that occurs during embryogenesis. Furthermore,
the finding that the reactivity of AID towards C5-substituted cytosine decreases with increasing
size of the substituent, makes it doubtful that AID plays a role in deaminating 5hmC, 5fC or
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5caC in DNA(127,128). An analysis of the methylome in AID-/- mice also did not support its role
in DNA demethylation(132). Despite these negative results, persistent reports suggest that AID
may play a role in DNA methylation changes at a limited number of loci during cellular
differentiation and establishment of pluripotency(133-137). Whether this role is enzymatic or
structural remains unresolved at this time and availability of a mouse with catalytically inactive
AID may help answer this question.
1.2.4 Genome-wide mutations and strand breaks
A number of studies have shown that AID targets cytosines outside the Ig genes causing
mutations and strand breaks. Immunoprecipitation experiments showed that AID binds RNAP
II(138) and ChIP coupled with deep sequencing (ChIP-seq) analysis found that AID associates
with nearly 6,000 genes in stimulated murine B cells(139). The genes that recruited AID had a
corresponding mRNA abundance that is 40 times greater than that of genes that do not recruit
AID. In elongating genes, AID and RNAP II peak at the transcription start sites (TSS), and AID
occupancy mirrors RNAP II density along the genes. A limited number of genes that recruit AID
were sequenced and were found not be hypermutated in stimulated wild-type B cells. However,
in UNG−/− background some non-Ig genes accumulated mutations at frequencies only ~10-fold
lower than in the Sμ region(139).
In another study, 1 kbp segments near 5’ ends of over 80 genes that are expressed in
germinal centers were sequenced from B cells undergoing maturation and 19% non-Ig genes
were found to be significantly mutated. The genes BCL6, CD83 and PIM1 had the highest level
of AID-dependent mutations, while many genes including H2AFX had background mutation
frequency(140). MYC gene was modestly, but significantly, mutated(140). However, the
frequency of mutations in the Jh4 region in the VDJ segment was greater than 40 times the
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frequency in any other gene demonstrating that the VDJ segment is far and away the best target
for hypermutations caused by AID in activated wild-type (WT) B cells. When the same genes
were sequenced from cells of UNG-/- MSH2-/- mice, the percentage of genes with significantly
higher mutations than background increased to 43%. However, in this background, BCL6, CD83
and PIM1 acquired mutations at only 1.6-fold the frequency found in WT cells. In contrast,
mutation frequencies of several other genes were dramatically higher in the UNG-/- MSH2-/cells. For example, frequency of mutations in the H2AFX and MYC genes respectively increased
18- and 14-fold(140) Together these results show that AID deaminates cytosines in many non-Ig
genes expressed in germinal center B cells, but high fidelity repair of the resulting uracils
prevents mutations in most genes. However, uracils in several other genes are processed in the
same error-prone manner as those in the V(D)J segment resulting in mutations (Figure 1.5). The
factors that determine whether or not a U•G pair in a genomic region will be repaired through
high fidelity repair have not been identified. It will also be useful to have results from a whole
genome sequencing study of this kind to determine the genic and non-genic targets of AID and to
delineate the features that make genomic regions susceptible to error-prone or high-fidelity
repair.
As mentioned earlier, B cell stimulation results in the creation of strand breaks outside
the Ig genes, which are repaired through homologous recombination prior to DNA
replication(118), but the location and numbers of these breaks have not been determined. In other
studies, the locations of double-strand breaks generated by AID in the murine genome were
determined by capturing them as translocations to engineered SceI endonuclease generated
breaks(141,142). Although, a large fraction of AID-generated breaks were within the Ig loci, the
remaining breaks were distributed throughout the murine chromosomes and correlated with
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actively transcribed genes. The frequency of AID-generated breaks peaked a few hundred bp
downstream of TSS and correlated with hypermutated genes(141,142). These and other studies
show that AID can target non-Ig genes and cause strand-breaks(97,101).
1.2.5 Cancer
While normal circulating B lymphocytes have undetectable levels of AID expression,
most non-Hodgkins B cell lymphomas (B-NHLs) express AID at high levels(143-147). These
cells also show evidence of germinal center development such as SHM or CSR, or both.
Additionally, their genomes contain translocations and non-Ig hypermutations. Typically, the
translocations involve recombination between an Ig gene and a protooncogene such as MYC,
BCL2 or BCL6(148,149). The biochemical steps leading from AID promoted DSBs to
chromosome translocations have been reviewed extensively(150-152).
In an IL6tg murine B cell plasmacytoma model, a critical step in cellular transformation
was dependent on AID. When mice are treated with pristane, a chemical that causes chronic
inflammation, or interleukin-6 (IL6), the animals acquire plasmacytomas and the tumors contain
IgH-MYC translocations(153,154). However, these translocations were not found in IL6tg AID-/mice and the formation of lymphatic hyperplasia was delayed in these mice(155). AID promotes
the formation of these translocations by creating DSBs at both Myc and IgH loci(156). AID was
also required for germinal center-derived lymphomagenesis in a different lymphoma-prone
mouse model(157). These mice expressed BCL6, which is a master regulator of germinal center
development and inhibits apoptosis. These and other results show that the principal role of AID
in causing B cell non-Hodgkin’s lymphomas is the ability of AID to generate DSBs near Myc,
BCL6 and other oncogenes causing translocations that result in their dysregulation. In contrast,
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absence of AID had no impact on Myc-driven, pre-GC (germinal center) lymphomas(157),
suggesting that only GC-derived B cell lymphomas depend on the expression of AID.
AID may play other roles in carcinogenesis in addition to promoting translocations.
When bone marrow cells transduced with AID were transplanted into immune cell-depleted
mice, the mice developed both B and T cell lymphomas(158). The B cell lymphomas contained
base substitution and addition/deletion mutations in genes EBF1 and PAX5 that are normally
expressed in B cells, but did not contain Myc-IgH translocations. This suggests that the ability of
AID to cause mutations may also play a role in tumor promotion(158).
Somewhat surprisingly, constitutive expression of AID in transgenic mice causes T cell
lymphomas, but not B cell lymphomas(159). These mice also develop lung microadenomas and
adenocarcinomas and, less frequently, develop other types of tumors such as hepatocellular
carcinomas, melanomas, and sarcomas(160). In these mice, genes for T-cell receptor (TCR),
MYC, PIM1, CD4, and CD5 were extensively mutated, but no large-scale clonal chromosome
rearrangements such as IgH-MYC translocations were found(161,162). These studies show that
ectopic expression of AID can contribute to carcinogenesis, but is not sufficient for B cell
cancers. As described above, a coordinated expression of other proteins such as BCL6 may be
necessary to drive B cells to malignancy.
1.3 APOBEC1 (A1)
A1 can deaminate cytosines in both ssDNA and RNA(3,9). In humans, A1 is expressed
only in the small intestine, but in rodents it is expressed in multiple tissues including the
liver(163).
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1.3.1 Lipid metabolism
The major physiological function of A1 is editing apolipoprotein B (apoB) mRNA and
this affects lipid metabolism and transport. ApoB mRNA editing occurs at high levels in small
intestine of all mammals and in the liver of dog, horse, rat and mouse. ApoB protein is found in
two forms, ApoB-100 and ApoB-48. The larger ApoB-100 is synthesized in the liver and is the
major protein component of low density lipoproteins (LDL) and an important risk factor for
atherosclerosis. The truncated form ApoB-100, ApoB-48, which is identical to the N terminal
half of ApoB-100 is synthesized in the small intestine and is essential for chylomicron assembly
and secretion. Unlike ApoB-100, ApoB-48 lacks the LDL receptor binding domain and as a
result, ApoB-48 containing lipid vesicles are rapidly cleared from circulation(164).
A1 is the catalytic component of a complex that also contains auxiliary proteins including
ACF (APOBEC1 complementation factor) and ASP (APOBEC1 stimulating protein)(165,166).
A1 deaminates cytosine in the codon 2153 (C6666AA) in ApoB mRNA to uracil creating an inframe stop codon(9,167). This causes a premature translation termination and creation of the
shorter apoB-48 protein. Recent studies show that in addition to apoB mRNA, A1 can deaminate
cytosines in several other RNAs,(168,169) but the biological function of these other RNA editing
events remains to be elucidated.
Apart from editing cytosines in RNA, A1 also has the ability to deaminate cytosines in
DNA(63). The target sequence context is different for RNA and DNA. Whereas the target
cytosine in ApoB mRNA is flanked by an adenine on the 5’ side, E. coli genetic assays and
biochemical assays with purified protein suggest that in DNA the preferred 5’ nucleotide is a
pyrimidine(7,63). The physiological function of DNA editing by A1 has not been established.
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1.3.2 Cancer
An early investigation of transgenic mice and rabbits expressing A1 found that the
animals showed liver abnormalities and developed hepatocellular carcinoma(170). Mice
expressing a truncated form of A1 did not show these abnormalities. In addition to the editing of
apoB mRNA, other mRNAs in the liver were found to be edited in transgenic mice(170). At the
time of these studies A1 was known to act only on RNA and hence the malignant
transformation was attributed to aberrant editing of mRNA for a protein with homology with a
translation factor(169,170). There is a need to revisit this issue by determining genomic uracils,
mutations and genomic rearrangements in hepatic carcinoma created by the dysregulation of
A1. A recent report shows A1 overexpression in esophageal adenocarcinoma but further studies
are needed to evaluate the contribution A1 expression to carcinogenesis.
1.4 APOBEC3 subfamily
There is currently no authentic animal model for the studies of individual APOBEC3 genes
and proteins because rodents have a single APOBEC3 gene, while humans have seven
APOBEC3 genes(171). Consequently, most experiments with human APOBEC3s are done using
primary or immortalized cells of human or non-human origin, and the results are often dependent
on the specific cell line being used. This has created significant confusion regarding the
expression of some the APOBEC3 proteins and their biological function.
1.4.1 Effects of cytokines and phorbol esters on the expression of APOBEC3 genes
Several APOBEC3 genes are upregulated in response to cytokine treatment of cells. While
some APOBEC3 genes are expressed constitutively in some tissues, expression of other
APOBEC3s is cytokine responsive(172,173).
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The genes for A3A, A3F and A3G, but not A3B or A3C, are upregulated by IFN- in
several hematopoietic cells including dendritic cells, macrophages and naïve CD4+ T
cells(173,174). IFN- enhances A3G expression in cells that are targets of HIV-1 infection,
resting

CD4+ T

cells(175),

human

peripheral plasmacytoid dendritic

cells(176)

and

macrophages(177,178). Moreover, IFN- and IFN- enhance the expression of A3F and A3G in
primary human brain microvascular endothelial cells, the major component of blood-brain
barrier, presumably to restrict HIV-1 entry into the central nervous system(179). A3G is also
induced by several other factors including IL-2, IL-15, and to a lesser extent IL-7, in peripheral
blood lymphocytes and by TNF- during the maturation of dendritic cells, which are different
cellular targets of HIV-1(174).
HBV infection of hepatocytes results in expression of cytokines and various APOBEC3
proteins. A3G gene has an IFN response element and its expression is upregulated upon
stimulation of cells with IFN-(180). In primary human hepatocytes or HBV infected liver cells
A3A, A3B, A3F and A3G expression is induced by IFN-(181,182). Additionally, treatment of a
cervical keratinocyte cell line that contains episomal HPV16 genomes with IFN-β results in
increased expression of A3A, A3F and A3G genes(183). The studies described above
collectively show that expression of APOBEC3 genes is an important part of cytokine-mediated
inflammatory response.
Phorbol esters are also known to induce APOBEC3 gene expression. A3A was first
identified as a highly expressed protein when primary human keratinocytes were treated with
phorbol esters such as phorbol 12-myristate 13-acetate (PMA) and was called Phorbolin1(184,185). Later, A3G was found to be upregulated in response to PMA in human T
lymphocytic cell lines(186). A3B expression also increased in many cell lines in response to
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PMA treatment with the largest effect seen in normal breast epithelial cell line MCF10A(187).
These findings suggest that APOBEC3s are upregulated upon treatment with cytokines or
phorbol esters in a cell type-specific manner.
Signal transduction pathways that control expression of APOBEC3 in response to
cytokines or phorbol esters have not been studied extensively. However, many cytokines and
phorbol esters are known to promote gene expression through signal transduction pathways
regulated by protein kinase C (PKC)(185-187). PKC pathway activates several different
transcription factors including NF-B (via canonical and/or non-canonical pathways) (182,187),
mitogen-activated protein kinases and the extracellular signal-regulated kinase(186) and these
transcription factors, in turn, are likely to be responsible for the expression of APOBEC3 genes.
1.4.2 Clearance of foreign DNA
There are several mechanisms in mammals to detect and eliminate foreign DNA circulating
in bodily fluids. Dendritic cells and macrophages detect foreign DNA unmethylated at CpG
sequences through toll-like receptor 9 in endosomal compartments(188). Additional DNA
sensors include the complex “stimulator of interferon genes” (STING), “DNA-dependent
activator of IFN regulatory factor” (DAI), “absent in melanoma-2” (AIM2) and RNAP III(189191). Together they participate in signaling pathways that produce pro-inflammatory cytokines
and chemokines such as TNF and type I interferons resulting in the transcription of effector
genes to elicit a broad innate immune response(190,192-194). The subsequent steps in the
process of clearance of foreign DNA are less characterized, but APOBEC3 proteins may play a
role in it.
Expression of A3A increases more than 100-fold in response to interferon treatment of
monocytes and macrophages, which ingest foreign objects like bacteria and viruses(172,195).
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A3A expression affects the integrity and stability of foreign DNA reducing gene transfer
efficiency, inhibiting transient gene expression and destabilizing foreign plasmid DNA.
Differential DNA denaturation PCR (3DPCR) and an UNG inhibitor were used to demonstrate
that the foreign DNA underwent deamination of cytosines to uracils(195). A subsequent study
showed that A3A expressed in monocytes was predominantly cytoplasmic and its optimal
activity occurred in acidic pH range found in endosomes(20,196). Methylation of CpGs
suppresses cellular recognition of foreign DNA(197) and among the AID/APOBEC family
members, A3A is most efficient at deaminating 5mC(10,198,199). This raises the interesting
possibility that the ability of A3A to deaminate 5mCs in DNA is related to clearance of viruses
that carry CpG methylation.(200) Family members such as A3G would be ineffective at this task
because of their inability to deaminate 5mC(10).
1.4.3 Immunity against RNA viruses
APOBEC3 subfamily proteins contribute to innate immunity by restricting viral infection
and propagation(66,201). The first APOBEC3 protein shown to have activity that restricts HIV-1
infection was A3G(202). Restriction of HIV-1 by APOBEC3s has been reviewed
extensively(203-205).
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Figure 1.7. APOBEC3G and Vif are key determinants of retroviral infectivity. This figure
presents a model that depicts how the APOBEC proteins and Vif (virion infectivity factor) can
influence the retroviral life cycle. Figure adapted from reference (16) with permission from
copyright clearance center.
Briefly, early work showed that A3G protein is incorporated into HIV-1 particles and
during reverse transcription of the viral RNA; A3G deaminates cytosines in minus-strand DNA
to cause G to A mutations(206,207) and creates non-infectious virions (Figure 1.7). Additionally,
it has been suggested that excision of uracils created by APOBECs by the cellular uracil-DNA
glycosylase may result in the degradation of viral DNA(208). However, the reverse transcription
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of viral RNA takes place in the cytoplasm and only mitochondrial (UNG1) and nuclear (UNG2)
forms of UNG have been described previously(209). Thus the interaction between the UNG
protein and the DNA copy of the viral genome needs to be studied in greater detail.
HIV-1 encodes the protein Vif that abrogates restriction of HIV-1 by A3G and other
APOBEC3 family members(208) and thus the above-mentioned experiments were done using
Vif– strains of HIV-1. Vif prevents A3G incorporation into the progeny virus and directs its
degradation by a proteosome-dependent pathway(210-212)(Figure 1.7). The interactions of Vif
with CUL5-RBX2, ELOB-ELOC and CBFβ to form ubiquitin ligase E3 and its interactions with
APOBEC3 family proteins has been described in detail(203,213-216) and will not be described
further.
A3D, A3F and A3H haplotypes II, V and VII, may also provide protection against Vifdeficient HIV-1 in tissue culture models(217). Using humanized mouse models it was also
shown that several APOBEC3 enzymes (A3G, A3D, A3F) can restrict HIV-1 in vivo(218). Some
studies also report that A3A, A3B and A3C are capable of inhibiting HIV-1
infection(203,219,220), but their significance is controversial(221,222). This is partly because
some members, including A3B, are able to inhibit wild type Vif-proficient HIV-1, but are not
normally expressed in T cells that are the primary targets of HIV-1 infection(220).
Subsequently, HIV-1 restriction was also observed with catalytically defective variants of
A3G and A3F (223,224), hence a deaminase independent mechanism may also inhibit HIV-1
growth. The prevailing model to explain this phenomenon invokes binding of APOBEC protein
to viral RNA and blocking the reverse transcription of viral genome(224-226). In summary, in
CD4+ T cells both editing and non-editing mechanisms mostly by A3G, and to lesser extent by
A3F and A3D, contribute to the restriction of Vif-defective HIV-1(226).
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In addition to HIV-1, APOBEC proteins have been reported to restrict or mutate a broad
range of RNA viruses including other retroviruses such as human T-cell leukemia virus type-1
(HTLV-1)(227-229) and simian foamy virus(230). A3G appears to play a major role in
restricting both HTLV-1(228) and simian foamy viruses(230). Also, other reports suggest that,
like HIV-1, these viruses may also express proteins that counteract the A3G protein(231-234)
and hence this issue needs further examination.
1.4.4 Immunity against DNA viruses
DNA viruses including adeno-associated virus (AAV), hepatitis B virus (HBV), human
papillomavirus (HPV) and herpes viruses such as herpes simplex-1 (HSV-1) and Epstein-Barr
Virus (EBV) have been reported to be restricted by APOBEC3s(66,201,235).
AAV is a nuclear replicating parvovirus that is restricted by A3A, but not A3G(236,237).
3DPCR was used to show that the genome of another nuclear replicating virus, HBV, mutated at
different levels by a number of APOBECs including A3A, A3B, A3C, A3F and A3G(238,239).
Cytokine-mediated upregulation of A3A and A3B results in the degradation of HBV covalently
closed circular nuclear DNA without apparent damage to the host genomic DNA(182).
HPV is a double stranded DNA virus that infects skin cells and infection of keratinocyte
cell line with HPV E6 results in expression of A3B(240). Again, 3DPCR was used to show that
HPV was hyperedited when A3A, A3B and A3H enzymes were transiently overexpressed(241).
In another study hypermutation of HPV16 in cervical keratinocytes were seen when A3A, A3F
and A3G were upregulated following IFN-β treatment(242). Both HSV-1 and EBV genomes
may be susceptible to editing by A3C expressed in HeLa cells and overexpression of A3C
through transfection results in the reduction of both viral titers and infectivity by HSV-1(243).
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Edited EBV DNA was also found in infected peripheral blood mononuclear cell lines in
association with high levels of A3C expression(243).
Although these studies collectively suggest that APOBEC3 proteins mutate many human
viruses, there are several concerns about these data. It is unclear how A3G, which is found
almost exclusively in the cytoplasm, can edit nuclear replicating EBV and HSV-1
viruses(238,243). There are also hints that, like HIV-1, other human viruses may employ
protective measures against APOBEC3 proteins and there is a need to investigate them further.
For example, most herpes viruses code their own UNG (vUNG) proteins that are expressed at the
onset of DNA replication. Furthermore, it has been shown that inactivation of vUNG in several
herpes viruses reduces viral replication(244-246). It would be interesting to investigate whether
vUNG proteins provide protection against the action of AID/APOBEC family enzymes on
herpes virus genomes.
Another significant concern is that a good deal of the work regarding antiviral effects of
APOBEC3s is based on analysis of mutations in viral genomes using the technique of
3DPCR(247). This technique uses lower than normal temperatures during the denaturation step
in PCR. The reason for lowering the denaturation temperature is that T:A pairs are energetically
less stable than C:G pairs and hence occurrence of C:G to T:A substitutions in a molecule lowers
its denaturation temperature. However, this has the effect that 3DPCR selectively amplifies the
small fraction of viral DNA molecules that contain multiple mutations. This has the potential of
exaggerating the mutational effects of APOBEC3s. It has also been shown that this procedure
introduces mutations in PCR products at a frequency of 1 in 500 bp (248), which is at least an
order of magnitude higher than normal PCR. It would be useful to use high fidelity PCR and
deep sequencing technologies to reexamine mutational effects of APOBEC3s in human viruses.
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1.4.5 Inhibition of retrotransposition
There are two major classes of retroelements in mammalian cells. One class includes
elements with long terminal repeats (LTRs) such as endogenous retroviruses and the second
class consists of non-LTR retroelements such as the long interspersed nuclear elements (LINEs)
and short interspersed nuclear elements (SINEs). APOBEC proteins inhibit retrotransposition of
both kinds of retroelements.
A3A, A3B, A3C, A3F and A3H have strong inhibitory effects on non-LTR
retroelements, specifically LINE-1 (L1) and Alu elements(249-252). A3A inhibits L1 by
deaminating transiently exposed ssDNA arising during retrotransposition.
A3B, A3C and A3F are thought to inhibit L1 transposition through a deamination-independent
mechanism(253,254). Although the involvement of A3G against non-LTR retroelements is
controversial (223,249,255), A3G can suppress the retrotransposition of mouse LTR
retrotransposons MusD and IAP as well as yeast Ty1 retrotransposon(256,257). Similarly, A3A,
A3B, A3C, A3D and A3F have been shown to inhibit LTR retrotransposition(223).
While 42% of the human genome is made up of retroelements, about 3% of the genome
consists of DNA transposons(258). Thus, almost half the human genome consists of active and
inactive transposable elements, and mutational footprints of APOBEC3s can be found in many
such sequences(259). There is considerable evidence that the spread of these elements has
occurred sporadically in the evolution of eukaryotes including primates(260-262). It is possible
that the expansion of APOBEC3s from one or two genes in the common ancestor of mammals to
seven genes in primates(1) may be explained by bursts of retrotransposition activity over 100
million years of mammalian evolution.
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1.4.6 Genome-wide mutations and cancer
The potential of AID for causing mutations in the cellular chromosomes was recognized
even before the enzyme was discovered,(263,264) but similar hazard was not associated with the
other enzymes in the family for over a decade following their discovery. This slothful scientific
slumber was rudely disturbed by the publication by Nik-Zainal et al. describing several breast
cancer tumors with APOBEC3 mutational signatures(265). These whole-genome sequencing
(WGS) studies identified APOBEC3-specific mutational signature, C to T or C to G mutations in
TCW sequence context, in the tumor genomes and found that the mutations were often
clustered(265). Additionally, the TCW sequences in these mutational clusters tended to have the
target cytosines in the same DNA strand, a phenomenon referred to as strand-coordinated
mutations(265-267) Subsequently, this signature was also found in more than a dozen different
types of cancers including those of head-and-neck and cervix(266,268,269)(Figure 1.8).

Figure 1.8. APOBEC mutational signature in multiple types of human cancer. Signature 2 is
associated with APOBEC-induced mutations and was identified in different types of human
cancers. Figure adapted from reference (268) with permission from copyright clearance center.
Additionally, expression of A3B was correlated with occurrence of breast(270) and other
cancers,(266,269) and other studies have implicated both A3A and A3B in cancer genome
mutations(271,272). It should be noted that all the APOBEC3s with the exception of A3G have
essentially the same mutational signature,(3,16) and hence these mutations are collectively
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referred to as APOBEC signature mutations(265). It is now clear that some members of the
APOBEC3 family play a significant role in causing mutations in cancer genomes(273), but
whether they play a role in driving carcinogenesis and tumor progression remains unclear.
However, evidence for a direct role for APOBECs in driving carcinogenesis may be found in the
analysis of HPV-positive head and neck cancers. These tumors show APOBEC-associated
mutations in a proto-oncogene, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
α (PIK3CA), at two helical domain hot spots (E542K and E545K)(274). These mutations weaken
the autoinhibitory interactions of this domain and hence APOBEC-mediated mutations appear to
activate this oncogene(274).
The processive behavior of APOBEC proteins(272,275) may be responsible for the
clustering of the observed mutations, but it is important to determine which cellular processes
create the extended ssDNA segments upon which the APOBECs act. One analysis of both breast
and lung tumor sequences found that mutations with APOBEC signature were more prevalent in
early replicating regions and that this was opposite of the distribution of most other somatic
mutations in these cancers which were found in late replicating regions(276). Furthermore, these
mutations were not correlated with transcription suggesting that they were unlikely to have the
same underlying mechanism as AID-generated genomic mutations. In a different study, A3A
was expressed from a tetracycline-controlled promoter and expressed either in cells blocked in
the G1 phase or released from G1 and allowed to enter the S phase. The latter cells acquired
more genomic uracils and strand breaks than the cells in G1(277). Together, these studies
implicate replication forks as targets for APOBEC3s(271).
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This correlation between replication and APOBEC-generated cytosine deaminations was
confirmed and extended through further analysis of strand-coordinated mutations in cancer
genomes with APOBEC signature(278,279). In both the studies, the origins of replication (ORI)
were assumed to lie at the intersection of replication timing versus distance plots for the left- and
right-replicating forks. Based on this identification of ORI, APOBEC signature mutations were
assigned to the two replication strands, the lagging strand template (LGST) and the leading
strand template (LDST). This analysis found that 50% to 100% more mutations were in the
LGST compared to the LDST(278,279)(Figure 1.9). This preferential targeting of LGST by
APOBEC3s may be explained by the fact that the LGST spends more time in a single-stranded
state than the LDST(280).

Lagging strand
template

Leading strand
template

Figure 1.9. A proposed model for APOBEC mediated deamination during DNA replication.
APOBEC enzymes deaminate cytosine in lagging-stand template to uracil during DNA
replication. Figure adapted from reference (278) with permission from copyright clearance
center.
Studies using yeast(281) and E. coli(282) genetic systems have provided strong
experimental evidence in support of this hypothesis. When A3G-CTD was expressed in an ung–
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mutant E. coli and the resulting mutations were determined by WGS in 50 independent cell lines
grown for over 1,000 generations, the resulting C:G to T:A mutations showed a strong strand
bias. There were 3- to 4-times as many transition mutations with the cytosine in LGST than in
LDST(282). The bulk of the C:G to T:A mutations were in runs of C’s indicating that they were
likely to have been caused by A3G-CTD and the strand bias was greatly diminished when a
catalytically defective mutant of the deaminase was expressed in the cells(282).
When the catalytic domain of A3G (A3G-CTD) was expressed in an engineered ung1
yeast strain, the mutation frequency in a reporter gene in the ssDNA region generated through
aberrant resection of telomeric ends increased substantially(283). This showed that A3G can
target ssDNA in the yeast genome. In a different study, expression of A3A or A3B in an ung1defective, but otherwise normal, yeast strain produced strand-coordinated mutations linked to
replication(281). The mutations were predominantly G:C to A:T when the reporter gene was on
the 5’ side of ORI, but C:G to T:A mutations dominated when the same reporter was on the 3’
side of the ORI. Furthermore, destabilization of replication through the use of yeast mutants
defective in RPA, the single-strand DNA-binding protein, or Tof1, a protein that couples
replicative polymerases with the helicase that opens the replication fork, increased the frequency
of mutations caused by A3A and A3B(281). A large increase in mutation frequency was also
seen when the cells were treated with hydroxyurea, a chemical known to cause replication stress.
Unexpectedly, the strand bias in mutations disappeared on the 5’ side, but not the 3’ side, of the
ORI in both the Tof1 mutant strain and in cells treated with hydroxyurea(281). Finally, the
strand-coordinated mutations caused by A3A and A3B were more often clustered when the
replication fork was disturbed compared to untreated wild-type cells and are reminiscent of the
clustered mutations seen in cancer genomes(265).
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Figure 1.10. Consequences of cytosine deamination at a replication fork. A replication fork
with cytosines in the leading strand template (LDST) and the lagging strand template (LGST) are
shown. The closed arrow-head represents the helicase that opens the DNA and is pointed in the
overall direction of replication. AID/APOBEC proteins deaminate cytosines in LGST and the
resulting uracils are either copied during replication (upper branch) or undergo repair (lower
branch). Replication without repair results in C:G to T:A mutations in the LGST. Alternately,
uracil-DNA glycosylase (UNG) may excise the uracils and the resulting abasic sites may be
copied by translesion synthesis (TLS) polymerases creating mutations (downward arrow). The
predominant mutations caused by polymerases η and REV1 are shown. AP endonuclease may
nick the DNA at the abasic site and this will lead to double strand (DS) breaks in DNA and cause
replication fork to collapse.
The model in figure 1.10 can explain mutations and strand breaks observed in dividing
cells expressing APOBECs. Most cytosines in the LDST will be inaccessible to APOBECs
because they will be in double-stranded DNA. Cytosines in the single-stranded gaps between
Okazaki fragments will be deaminated by the APOBECs and most of these uracils will be copied
immediately by the replicative DNA polymerase  creating C:G to T:A mutations. Occasionally,
UNG2 may excise the uracil before a polymerase has a chance to copy it, and the resulting AP
site may be copied by TLS polymerase  again creating the same mutation in most cases(79).
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Alternately, the AP site may be copied by REV1 creating C:G to G:C transversions(80,81).
Finally, if AP endonuclease APE1 acts on the AP site before TLS bypass of the AP site, a double
strand break will occur (Figure 1.10). These may be the strand breaks observed by Green et
al.(277) when they expressed A3A in the S phase. Thus expression of APOBECs during
replication should cause genome instability in addition to generating mutations.
In contrast to these results in dividing cells, Lada et al. found that genome-wide
mutations caused by the lamprey DNA-cytosine deaminase, PmCDA1, in non-dividing yeast
were often clustered and the occurrence of clusters was correlated with known transcription
levels of the target genes(284,285). Furthermore, more mutations were in the 5’-UTRs than in
the bodies of the genes, and there were substantially more C to T mutations in the nontranscribed DNA strand than in the transcribed strand in all the parts of the genes(284). This
result is well-explained by the observation that the non-transcribed strand is more susceptible to
damage than the transcribed strand(89,286) (Figure 1.6). Together, these observations suggest
that in dividing cells, the APOBEC enzymes preferentially target cytosines in the LGST, but in
non-dividing cells the preference may shift to cytosines in the non-transcribed strand of actively
transcribed genes.
1.4.7 Linking virus infection, APOBEC3 expression and cancer
As mentioned above, there is currently no animal model for studying the role of APOBEC3
proteins in carcinogenesis. However, a number of lines of evidence suggest that these proteins
play an important role in promoting malignant transformation.
About 15-20% of human cancers are attributed to viruses(287) and these tumor viruses are
distributed throughout DNA and RNA virus families(288). They include DNA viruses such as
HPV, HBV, EBV and human herpes virus 8/ Kaposi’s sarcoma-associated herpes virus, and
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RNA viruses including human T-lymphotrophic virus-1 and Hepatitis C virus (HCV)(289).
However, virus infected cells launch an innate immune response, in part, by releasing cytokines
such as interferons and interleukins(290). In general, the release of these cytokines has been
linked to cancer through the generation of oxidative stress, stimulation of pro-growth signal
transduction pathways, and synthesis of chemokines and growth factors(290,291). While it is
possible that these molecules and pathways play other roles in causing DNA damage and
promoting cancer, expression of AID/APOBEC proteins may also play a role in this
transformation.
As discussed in section 1.3.1, cytokines produced during viral infections trigger the
expression of AID/APOBEC proteins and as discussed in sections 1.2.4 and 1.3.6 these enzymes
can cause genome-wide mutations. Therefore, AID/APOBEC expression could be a key link
between viral infection and malignant transformation (Figure 1.11).
There are several recent reports linking APOBEC proteins to virus-driven tumor
development, especially with HPV and HBV. Expression of APOBEC proteins and mutational
signatures occur at high frequency in HPV-positive cervical and head and neck
cancer(268,269,274,292). Association between APOBEC enzymes in HBV driven hepatocellular
carcinoma has been reviewed extensively(235,239,293). What remains unclear at this point is
whether or not APOBEC enzymes cause a significant fraction of the driver mutations or genome
rearrangements seen in cancers. APOBEC associated mutations observed in proto-oncogene
PIK3CA provide some evidence for APOBEC activity as a key driver of mutagenesis in HPVinduced transformation(274). Regardless, there is an urgent need for the development of new
animal models to study the link between APOBEC enzymes and cancer.

40

Figure 1.11. Linking viral infection, AID/APOBEC expression and cancer. During viral
infection cytokines (yellow triangles) trigger the expression of AID/APOBEC proteins (purple
ovals) via NF- κB pathway. These enzymes damage the viral genome (red star) and promote
creation of high affinity antibodies against the virus. This helps the body clear the virus.
Additionally, off-target damage to cellular DNA leads to mutations and strand breaks resulting in
genome instability. This may lead to cell death or malignant transformation.
1.4.8. Functional convergence of AID and APOBEC enzymes
The AID/APOBEC field was trifurcated at its birth. RNA and lipid biochemists who
study RNA editing by A1 and its role in lipid metabolism reside on the first leaf of this three-leaf
clover. One report showed 20 years ago that A1 may cause liver cancer, but there have been no
further reports confirming or refuting this observation. There have also been few studies of the
effects of A1 expression on cellular genome mutations. Virologists have resided on the second
leaf of this Shamrock studying the role of APOBEC3 subfamily in innate immunity and
inhibition of virus growth. Although APOBEC3 family members were shown to bind RNA and
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this binding has a role in antiviral function of the proteins, no evidence was presented that they
may act as RNA-cytosine deaminases. The possible role of APOBEC3 enzymes in causing
genomic mutations and promoting cancer was also rarely examined. On the last leaf of this
Shamrock lie immunologists and tumor biologists who are focused on the role of AID in
antibody maturation and B cell cancers. The studies of the role of AID in carcinogenesis have
focused on DSBs and translocations with only a few studies exploring the non-Ig gene
mutations. Despite an early observation that AID binds RNA(4), the functional significance of
this observation was not explained.
Luckily, a number of recent studies suggest that this separate progress in the three
separate fields is about to converge, especially when it comes to AID and APOBEC3 enzymes.
Recently, A3A and A3G were implicated in C to U editing in RNA(11,294,295) and, more
surprisingly, in G to A editing in RNA(296). Additionally, AID was shown to bind intronic RNA
from the switch regions and the evidence suggests that this bound RNA guides the enzyme to the
switch regions and is essential for CSR(297). It is likely that all members of the AID/APOBEC
family bind RNA and this binding is biologically relevant. The implicit assumption that
APOBEC3 enzymes act only on viral or retrotransposition intermediates must be set aside in
view of the work of Nik-Zainal et al.(265) and others. Interestingly, the APOBECs were shown
to act at replication forks(278,279,281,282) creating a contrast with AID which was known to act
only on actively transcribed genes. However, Le and Maizels(298) recently showed that this
dichotomy is not dictated by the biochemistry of AID, but is probably the result of the
degradation of AID in the S phase. If AID is made stable in the S phase, it causes strand breaks
in the same way as A3A(277,298). Lastly the link between the expression of AID and
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APOBEC3s with inflammation suggests that they may share more unexplored biology than
previously suspected.
1.5 Specific aims and significance of the dissertation work
The AID/APOBEC family is unique among all known enzymes in that most members of
this family cause damage to a DNA base and the biological purpose of this action is to cause
base substitution mutations and strand breaks. Vertebrates express these enzymes to gain
immunity against infections and Homo sapiens appear to have the highest number of genes for
these enzymes. However, this protective strategy requires that these enzymes perform a highwire act in which they mutate the foreign genomes (or the host Ig genes) without damaging much
of their own genome. This is the genetic equivalent of playing with fire and it is increasingly
becoming clear that it fails in some cells and they get badly burnt. In particular, many members
of the AID/APOBEC family are implicated as the source of mutations found in many cancers
and some of these mutations may drive carcinogenesis. We need to learn a great deal more about
the regulation of these enzymes in response to infections, the role of different family members in
restricting different human viruses under biologically relevant conditions, the kind and amount
of damage they cause to the host genome, the cellular mutation avoidance mechanisms that limit
such damage, and the contributions of the DNA damage that escapes repair to cellular
dysfunction including their malignant transformation.
In order to address these areas that are not well studied in the AID/APOBEC field, I
initiated two major projects as my dissertation work .
Project 1. Defining the catalytic domain of human APOBEC3B and determining its
substrate specificity.
It was recently reported that aberrant expression of A3B can induce somatic mutations in
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the human genome, ultimately leading to cancer such as breast cancer(269,270). Therefore
research to understand structure and activity of A3B in depth has gained much attention by the
scientific community. There are several studies reporting the purification and biochemical
characterization of some AID/APOBEC family proteins including A3A, A3F and A3G.
Additionally there are X-ray crystal structures (A3G-CTD, A3F) or NMR based structures
(A3A) for these enzymes. In contrast, during the time of this study, A3B has not been purified to
homogeneity and characterized at the biochemical level. As discussed in chapter 2, to better
understand the catalytic and structural properties of A3B, I used genetic and biochemical tools to
identify the CTD with the highest mutational activity, purified it to homogeneity and determined
its kinetic parameters. Then the intrinsic deamination activity of NTD was also re-examined by
genetic and biochemical studies. Finally A3B was tested for its ability to deaminate 5mC
compared to A3A which has shown the highest 5mC deamination ability among the APOBEC3
family members.
By completing this project I have provided a comprehensive report on in vitro biochemical
characterization of maximally active catalytic domain of A3B. Since there was no crystal
structure available for A3B at the time of this project, the outcomes of this study help broaden
our knowledge on structural organization of this protein, specially by identifying a novel
structural role of a methionine at the junction of its NTD and CTD. Furthermore, this knowledge
can also be applied to other APOBEC3 members as they show high level of sequence homology.
Purification of full length A3B is challenging due to its toxic nature and poor solubility.
Therefore defining a maximally active catalytic domain of the protein which can be purified to
homogeneity will allow researchers to use it for further biochemical characterization,
crystallization or functional analysis. Moreover, A3B is the only APOBEC that shows
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constitutive nuclear localization(299,300). Therefore identifying A3B as a poor 5-methylcytosine
deaminase suggest that A3B is unlikely to play a major role in DNA demethylation or causing
mutations at methylated CpG sites in the human genome.
Project 2. Determine the effects of inflammatory stimuli on APOBEC3 expression and its
consequences on genomic DNA.
There is no animal model that demonstrates the role of APOBEC3s in cancer. This is
largely because only primates carry multiple A3 genes while other mammals have a single A3
gene(301). Thus the expression of human A3s in rodents is likely to result in non-physiological
effects. Despite this limitation, whole genome sequencing has identified APOBEC mutational
signatures in cancer cell lines or patient tumors. Although such studies are informative, they do
not tell us what happens in a normal cell prior to its transformation to a cancer cell.
As discussed in chapter 3, to address the consequences on genomic DNA due to
APOBEC3 upregulation in normal cells, inflammatory stimuli such as various cytokines and
certain chemicals were used to induce expression of APOBEC3 enzymes. Cytokine-mediated
inflammatory responses are the first line of defense against viral infections and many APOBEC3
family members are expressed in cells in response to treatment of pro-inflammatory
treatments(172).
It is well established that these enzymes are potent mutators of viral DNA, but it is
unclear whether their editing activity is a threat to the integrity of the cellular genome. If any one
or more APOBEC3 enzyme/s are overexpressed and able to mutate the genome, multiple types
of damage may accumulate. To test this notion, during the second project, the genomic damage
caused by these enzymes, specifically by A3A was quantified as uracils in DNA. The finding
that cessation of DNA replication prevent A3A mediated uracil generation provides an attractive

45
mechanism for protection against APOBEC enzymes. On the other hand, overexpression of
APOBEC enzymes in tumor cells which are evolved to divide rapidly would result in mutations
and strand breaks. This phenomenon can be used as a "Therapy by hypermutation" strategy to
promote cancer cell killing, although with the potential risk of genetic diversification and drug
resistance in tumors(302).
Together these studies discussed in the dissertation provide insights into the structural
organization and functions of APOBEC3 family proteins and their effects on genome integrity.
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CHAPTER 2: CHARACTERIZATION OF THE CATALYTIC DOMAIN OF HUMAN
APOBEC3B AND THE CRITICAL STRUCTURAL ROLE FOR A CONSERVED
METHIONINE
Portions of the text and figures in this chapter were reprinted or adapted with permission from:
Siriwardena, S. U.; Guruge, T. A.; Bhagwat, A. S., Characterization of the Catalytic Domain of
Human APOBEC3B and the Critical Structural Role for a Conserved Methionine. J Mol Biol
2015, 427 (19), 3042-55.
Copyright 2015, Elsevier Ltd.
2.1 Introduction
APOBEC3B (A3B) belongs to the AID/APOBEC family of DNA-cytosine deaminases
that has 11 members in Homo sapiens and other primates(2,301). A3B converts cytosines in
single-stranded DNA to uracils and is part of the innate immunity response of the organism. It
mutates and restricts viruses such as HIV-1 and hepatitis B(220,222) and also inhibits
retrotransposition of endogenous retroelements(250,254,303). The seven human APOBEC3s can
be divided into two groups based on whether they contain one or two zinc-binding domains, and
A3B contains two such domains. Based on the properties of point mutations in the putative zincbinding residues, the carboxy-terminal domain (CTD) is thought to be responsible for the
catalytic activity of this enzyme(304,305). However, the amino-terminal domain (NTD) of A3B
does contribute to its antiviral activity(304) suggesting that both the zinc-binding domains play a
role in the immune function of the protein.
A remarkable recent finding is that many of the mutations found in a variety of cancer
genomes bear the signature of mutations caused by members of the AID/APOBEC
family(89,265,268,270). The most compelling evidence for an AID/APOBEC member to be the
causative agent for such mutations is found in breast cancers where ~50% of the tumor samples
and cell lines have elevated levels of APOBEC3B. Furthermore, Burns et al(270) found that two
of the breast cancer cell lines, MDA-MB-453 and HCC1569, have elevated levels of genomic
uracils that could be attributed to APOBEC3B. This raises the possibility that many of the
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“spontaneous” mutations acquired by cancer cells- and perhaps even by normal cells- may be
caused by A3B and other members of the AID/APOBEC family.
Several mutational studies of AID, A3G and some other members of this family have
defined the residues important for catalysis, DNA or RNA binding and their interactions with
HIV-coded protein Vif (reviewed in(2,203,208,306,307)). Additionally, A3A, A3F and A3G
proteins have been purified and studied using biochemical tools. Several X-ray crystallographic
or NMR-based structures of the catalytic domain of A3G are available(32-35,308). NMR-based
structures of A3A(24), and X-ray crystal structures of A3F(30) and APOBEC2(23) provide
insights into the structure-function relationships in this family of proteins.
In contrast, A3B has not been characterized at the biochemical level. The mutational
spectrum of A3B in virus genomes suggested that the enzyme deaminates cytosines in 5’-YC
sequence context (Y is pyrimidine) with a preference for TC dinucleotides(222). This
observation was confirmed in biochemical studies of protein containing residues Pro-195
through C-terminal end of A3B partially purified from mammalian cells(270,309). However at
the time of this study, full-length A3B, its NTD or CTD have not been purified to homogeneity
and characterized biochemically (see section 2.4 for the discussion on currently available crystal
structures of A3B-CTD). To better understand the catalytic and structural properties of A3B, we
initiated a study to define the catalytic domain of this enzyme. It was purified from E. coli to
homogeneity and was found to require residues upstream of Pro-195 for optimal activity. We
also determined kinetic parameters of the catalytic domain and tested the protein for ability to
deaminate 5-methylcytosines.
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2.2 Materials and methods
2.2.1 Bacterial Strains and Plasmids
E. coli K-12 strains BH214 and BH400 have been described previously(10). E. coli B strain
BL21(DE3) was used for protein expression and purification. The plasmid pUP31 contains an
inactive kanamycin resistance allele(310) and the plasmid pDCM21 carries the E. coli cytosine
methylase gene(311).
The full-length of APOBEC3B was amplified from the human APOBEC3B cDNA
purchased from OriGene Technologies (Rockville, MD) and cloned into vector plasmid pSU24
as HindIII-KpnI fragments. The primers used for the cloning are listed in Table 2.1. The
resulting clone, pSUA3B, was validated by sequencing (DNA sequencing core, University of
Michigan). The gene for the Ung inhibitor, UGI, was amplified from a plasmid kindly provided
by Umesh Varshney (Indian Institute of Science, Bangalore, India) and inserted at the KpnI site
in pSU24 or pSUA3B to respectively create pSU24-UGI or pSUA3B-UGI.
Mutants of pSUA3B (E255A, D194A, M193A, M193F, M193E) were constructed using the
Quickchange mutagenesis protocol (Agilent Technologies). The mutagenesis primers are listed
in Table 2.1. The A3B CTD gene fragments starting at amino acids 170, 180, 187, 193 and 195
were amplified from pSUA3B (Table 2.1), cloned into pSU24 and used in genetic reversion
assays. The gene fragments starting at 187, 193 and 195 were also cloned into pET28a(+) vector
(Novagen) as a XbaI-XhoI fragment to create a carboxy terminal poly-His tagged versions of the
proteins. The A3B NTD gene fragment (residues 1 through 192) was amplified and cloned into
pET28a(+) as a NdeI-XhoI fragment to create an amino terminal poly-His tag version of the
protein.
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Table 2.1. Primers used for cloning and site directed mutagenesis
Construct

Primer sequence

pSUA3B-FULL

FP 5'- GCG CGC GCA AGC TTA TGA ATC CAC AGA TCA GAA ATC CG -3'
RP 5'- GCG CGC GCG GTA CCT CAG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pSUA3B-NTD

FP 5'- GCG CGC GCA AGC TTA TGA ATC CAC AGA TCA GAA ATC CG -3'
RP 5'- GCG CGC GCG GTA CCT CAC AGG TAT CTG AGA ATC TCC TTT AGC -3'

pSUA3B(193382)

FP 5'- GCG CGC GCA AGC TTA TGG ATC CAG ACA CAT TCA CTT TCA AC -3'
RP 5'- GCG CGC GCG GTA CCT CAG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pSUA3B(195382)

FP 5'- GCG CGC GCA AGC TTA TGC CAG ACA CAT TCA CTT TCA AC -3'
RP 5'- GCG CGC GCG GTA CCT CAG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pSUA3B(187382)

FP 5'- GCG CGC GCA AGC TTA TGG AGA TTC TCA GAT ACC TGA TGG ATC CAG -3'
RP 5'- GCG CGC GCG GTA CCT CAG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pSUA3B(181382)

FP 5'- GCG CGC GCA AGC TTA TGC TGC ACC GCA CGC TAA AGG AGA TTC -3'
RP 5'- GCG CGC GCG GTA CCT CAG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pSUA3B(170382)

FP 5'- GCG CGC GCA AGC TTA TGC CTT GGT ACA AAT TCG ATG AAA ATT ATG C -3'
RP 5'- GCG CGC GCG GTA CCT CAG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pETA3B-NTD

FP
RP
3'

pETA3B(193382)

FP 5'- GCG CGC GCT CTA GAG AAG GAG ATA TAC CAT GGA TCC AGA CAC ATT CAC
-3'
RP 5'- GCG CGC GCC TCG AGG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pETA3B(195382)

FP 5'- GCG CGC GCT CTA GAG AAG GAG ATA TAC CAT GCC AGA CAC ATT CAC -3'
RP 5'- GCG CGC GCC TCG AGG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pETA3B(187382)

FP 5'- GCG CGC GCT CTA GAG AAG GAG ATA TAC CAT GGA GAT TCT CAG ATA CCT
G -3'
RP 5'- GCG CGC GCC TCG AGG TTT CCC TGA TTC TGG AGA ATG GCC CGC AG -3'

pSUA3BFull(E255A)

FP
RP

5'- GCG CGC GCC ATA TGA ATC CAC AGA TCA GAA ATC CGA TGG -3'
5'- GCG CGC GCC TCG AGT CAC AGG TAT CTG AGA ATC TCC TTT AGC GTG CG -

5'- GGC TTT TAC GGC CGC CAT GCG GCG CTG CGC TTC TTG GAC CTG G -3'
5'- CCA GGT CCA AGA AGC GCA GCG CCG CAT GGC GGC CGT AAA AGC C -3'
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pSUA3BFull(D194A)

FP 5'- GGA GAT TCT CAG ATA CCT GAT GGC TCC AGA CAC ATT CAC TTT C -3'
RP 5'- GAA AGT GAA TGT GTC TGG AGC CAT CAG GTA TCT GAG AAT CTC C -3'

pSUA3BFull(M193A)

FP 5'- GGA GAT TCT CAG ATA CCT GGC GGA TCC AGA CAC ATT CAC TTT C -3'
RP 5'- GAA AGT GAA TGT GTC TGG ATC CGC CAG GTA TCT GAG AAT CTC C -3'

pSUA3BFull(M193F)

FP 5'- GGA GAT TCT CAG ATA CCT GTT CGA TCC AGA CAC ATT CAC TTT C -3'
RP 5'- GAA AGT GAA TGT GTC TGG ATC GAA CAG GTA TCT GAG AAT CTC C -3'

pSUA3BFull(M193E)

FP 5'- GGA GAT TCT CAG ATA CCT GGA GGA TCC AGA CAC ATT CAC TTT C -3'
RP 5'- GAA AGT GAA TGT GTC TGG ATC CTC CAG GTA TCT GAG AAT CTC C -3'

2.2.2. Kanamycin-resistance Reversion Assay
The kanamycin-resistance (KanR) reversion assay has been described previously(312,313).
In this assay transition mutation at the second cytosine in an ACCA sequence in a plasmid-borne
kanamycin-sensitive allele restores wild-type amino acid sequence (phenotype- kanamycinresistant; KanR) and the mutant bacteria are selected on kanamycin plates (Figure 2.1).

Figure 2.1. Principle of Kanamycin-resistance Reversion Assay. Codon 94 of the Kanamycin
resistant gene is shown. KanR: Kanamycin-resistant, KanS: Kanamycin sensitive
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To quantify C to U deaminations, BH214 was cotransformed with different A3B constructs
along with pUP31. In some experiments A3B constructs carrying UGI gene were transformed
into BH400. To quantify 5mC to T deaminations, BH400 was cotransformed with a A3B
construct and pDCM21 and kanamycin-resistant revertants were scored. In all the experiments
KanR revertants were selected on LB plates with 50µg/mL of the antibiotic and KanR revertant
frequency was calculated as the ratio of number of KanR revertants/total number of viable cells.
2.2.3. Rifampicin-resistance assay
Full length A3B or its mutants (E255A, M193A and M193E) were transformed into the
strain BH214 and transformants were selected on LB plates containing 25 μg/mL
chloramphenicol. Independent transformants were picked and grown overnight in LB media
containing chloramphenicol. The following day, the cultures were diluted 1000-fold and were
grown at 37 °C until OD600 reached ~0.5 - 0.6. Appropriate dilutions of each culture were spread
on LB plates containing chloramphenicol to determine the total number of viable cells. The
cultures were also spread on LB plates containing 100 μg/mL rifampicin (Sigma-Aldrich) to
determine the number of rifampicin -resistant (RifR) colonies. Mutant frequency was obtained by
dividing the number of RifR colonies by the number of viable bacteria present in the culture.
2.2.4. Purification of A3B 193-CTD, 187-CTD and A3B NTD
BL21(DE3) cells expressing 187-CTD, 193-CTD, 195-CTD or NTD were grown to mid-log
phase and transcription was induced with the addition of IPTG to 0.4 mM. The cells were grown
overnight at 18°C and harvested by centrifugation. The cells were broken using the French
Pressure Cell Press (Thermo Spectronic) and the cell-free lysate was cleared by centrifugation.
The lysate was passed over Ni-NTA agarose resin (Qiagen) and the bound proteins were eluted
with 250 mM imidazole. The eluted proteins were dialyzed and concentrated using Amicon Ultra
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Centrifugal devices (EMD-Milipore, Billerica,MA). The concentrated proteins were equilibrated
in the storage buffer [20mM Tris-HCl (pH 8), 50mM NaCl, 1mM EDTA, 1mM DTT, 10%
glycerol].
The proteins 187-CTD and 193-CTD from the affinity column were loaded onto a
Superdex-75 column (GE Healthcare), the column was equilibrated in buffer [20mM Tris-HCl
(pH 8), 50mM NaCl, 1mM EDTA, 1mM DTT] and the proteins were eluted in same buffer.
Fractions of the eluate were analyzed by SDS-PAGE and the fractions containing protein of the
expected size were pooled and concentrated. Glycerol was added to 10% v/v and the proteins
were stored at -80°C in 50 L aliquots.
2.2.5. MALDI-TOF analysis of proteins
Isolated proteins were desalted using ZipTip C18 columns (Millipore Corp.) and 1 µl
samples were deposited on a polished steel MALDI target plate in 50% acetonitrile / 0.1% TFA.
The solvent was allowed to evaporate at room temperature and the samples were overlaid with 1
µl of matrix solution of saturated α-cyano-4 hydroxy-cinnamic acid (CHCA) in 50% acetonitrile
/ 0.1% TFA and were air dried at room temperature. The samples were analyzed using Ulrtaflex
MALDI-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) in LUMIGEN
instrument center (Wayne State University). The spectra were recorded in the manual linear
positive ion mode.
2.2.6 Size exclusion chromatography of the purified 193-CTD
The Superdex-75 column (GE Healthcare) was calibrated using the proteins Aprotinin (MW
6.5 kDa), Cytochrome c (12.4 kDa), Carbonic Anhydrase (29 kDa) and Albumin (66 kDa) from
a kit (MWGF70; Sigma Aldrich). The column void volume (V0) was determined using Blue
Dextran (MW 2000 kDa). A calibration curve was produced by plotting the logarithms of the
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known molecular masses of protein standards versus their respective Ve/V0 (Ve is the elution
volume). The 193-CTD protein purified to homogeneity over Ni-affinity and Superdex-75
columns was rechromatographed over the pre-calibrated Superdex-75 column. The protein
elution was monitored using absorbance at 280 nm and the molecular weights of the two peaks
were calculated from their Ve/V0 values using the calibration curve.
2.2.7 Biochemical assay for cytosine deamination
The substrates for the study of C and 5mC deamination are listed in Table 2.2. The
deamination assays with 187-CTD and 193-CTD were performed in the reaction buffer [20mM
Tris-HCl (pH 8.0), 1 mM EDTA, 1mM DTT] for the indicated lengths of time. The reactions
were terminated by heating them to 95 °C for 10 min. Following incubation of C-containing
oligomers with the protein, 2 units of E. coli Ung (New England Biolabs, Ipswich, MA) were
added to the reaction and incubation was continued at 37 °C for 30 min. The reactions were
stopped by adding NaOH to 0.1 M and heating to 95 °C for 10 minutes. The reaction products
were separated on a 15% denaturing acrylamide gel and visualized using Typhoon 9210
phosphorimager (GE Healthcare). ImageQuant software was used to quantify the intensities of
the substrates and the deamination products. These steps are illustrated in figure 2.2.

Table 2.2. Oligonucleotides used for in vitro deamination assays
Name

Sequence

TCGA-40

5'- ATT ATT ATT ATT ATC GAT TTA TTT ATT TAT TTA TTT ATT T -3' (6-FAM)

TUGA-40

5'- ATT ATT ATT ATT ATU GAT TTA TTT ATT TAT TTA TTT ATT T -3' (6-FAM)

TCAG-30

5'- ATT ATT ATT ATT ATC AGT TTA TTT ATT TAT-3' (6-FAM)
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TCGG-30

5'- ATT ATT ATT ATT ATC GGT TTA TTT ATT TAT-3' (6-FAM)

TUGG-30

5'- ATT ATT ATT ATT ATU GGT TTA TTT ATT TAT-3' (6-FAM)

TMAG-40

5'- ATT ATT ATT ATT ATM AGT TTA TTT ATT TAT TTA TTT ATT T -3' (6-FAM)
M= 5mC

TMGG-40

5'- ATT ATT ATT ATT ATM GGT TTA TTT ATT TAT TTA TTT ATT T -3' (6-FAM)
M= 5mC

TTGG-40

5'- ATT ATT ATT ATT ATT GGT TTA TTT ATT TAT TTA TTT ATT T -3' (6-FAM)

TCAG rev com

5'- AAA TAA ATA AAT AAA TAA ATA AAC TGA TAA TAA TAA TAA T -3'

TCGG rev com

5'- AAA TAA ATA AAT AAA TAA ATA AAC CGA TAA TAA TAA TAA T -3'

The kinetic parameters for cytosine deamination were determined using 193-CTD and three
different DNA oligomer substrates. For the TCGA-40 substrate 2 µM of A3B-193 was incubated
with increasing concentration of substrate (0.5 - 12 µM) for increasing lengths of incubation (5,
10 and 20 min) at 37 °C. For substrates TCAG-30 and TCGG-30 1.3 µM of A3B-193 was
incubated with increasing concentration of substrate (2 - 40 µM) for increasing lengths of
incubation (3, 5 and 10 min) at 37 °C. The products were separated on a gel and analyzed as
described above. The data were fitted to a linear regression and analysis was done using
GraphPad Prism to calculate the Vmax and KM values.
To study in vitro complementation of 193-CTD with A3B-NTD, 10 pmol of 193-CTD was
incubated with 2 pmol of TCGA-40 substrate along with different amounts of A3B-NTD (0 to 20
pmol). The amount of A3B NTD in the partially purified protein was determined by comparing it
to BSA standards. The reactions were performed at 37°C for 30 min and the products were
processed and analyzed as described above.
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Figure 2.2. Schematic representation of in vitro biochemical assays for cytosine (C) and 5methyl cytosine (5mC) deamination. The substrate oligonucleotide has a 3' fluorophore (6FAM, green star).
2.2.8 Biochemical assay for 5-methylcytosine deamination
The ∆399 construct containing the glycosylase domain of the murine MBD4 was purified
using a N-terminal poly-His tag as described previously(314). Briefly, the expression of this
protein was induced in BL21(DE3) cells using 0.4 mM IPTG and cells were grown overnight at
22 °C. Following purification of the protein using a Ni2+-affinity column it was purified further
to near homogeneity using size exclusion chromatography over a Superdex-75 column. The
protein was stored in a buffer containing 20 mM Tris-HCl (pH 8), 50 mM NaCl, 1 mM EDTA, 1
mM DTT and 50% v/v glycerol.
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To study 5mC deamination, 80 nM oligomer TMAG or TMGG (M is 5mC) was incubated
with indicated concentrations of purified 193-CTD at 37°C. All the reactions were terminated
after 30 min incubation and three-fold molar excess of the complementary strand (TMAG revcom or TMGG rev-com) was added to the reaction to create a T•G mismatch. The duplex was
incubated with 5 µl of purified MBD4 catalytic domain for 1 hour at 37 °C and the products
were processed and analyzed in a manner similar to the C deamination reactions (Figure 2.2).
2.2.9 Purification of APOBEC3A and deamination of C and 5mC by APOBEC3A
Purification of human APOBEC3A and biochemical assays of this protein have been
described previously(10). Briefly, BL21(DE3) cells expressing A3A with a C-terminal poly-His
tag were grown to mid-log phase and transcription of the A3A gene was induced with the
addition of IPTG to 0.4 mM. The cells were grown overnight at 18°C and the protein was
purified by Ni2+-affinity column. The partially purified protein was dialyzed against the storage
buffer [20mM Tris-HCl (pH 8), 50mM NaCl, 1mM EDTA, 1mM DTT, 10% glycerol] and stored
at -80C. The amount of A3A in the preparation was determined by SDS-PAGE of the partially
purified protein and its comparison with BSA standards. To study C and 5mC deamination by
A3A, 80 nM oligomer TCGG or TMGG was incubated with indicated concentrations of A3A at
37°C for 30 min.
2.2.10 Analysis of protein structures and homology modeling
The full sequences of A3A and A3C, and the CTDs of A3B, A3F and A3G were aligned
using Clustal-omega software(315) and the alignments were manually adjusted to reduce gaps.
PDB structures 2M65 (A3A), 3VOW (A3C), 4IOU (A3F CTD) and 3IR2 (A3G CTD) were
visualized and analyses were performed using the UCSF Chimera package (39). The
hydrophobic pocket surrounding the conserved methionine in each case was defined using the
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built-in hydrophobic surface module and all the relevant residues were labeled. The transparency
of the methionine was set at 90%, while the transparency of the residues forming the
hydrophobic pocket was set at 10%.
The structure of 193-CTD was generated using the homology modeling server Swiss
Model(316). The QMEAN4 score for the modeled structure was 0.54. The structure was opened
using UCSF Chimera, and analyzed and labeled in the same manner as the APOBEC3 members
with known structures. Superposition of modeled 193-CTD with a recently published crystal
structure of A3B-CTD was performed using PyMOL Molecular Graphics System(29).
2.3 Results
2.3.1 Defining the catalytic domain of APOBEC3B
Although structure-based analysis of APOBEC3 proteins suggests that the A3B CTD begins
at residue number 193(34,213) , it has been reported that a shorter version that starts at residue
number 195 is catalytically active(270,309). Consequently, we first cloned the gene fragment
containing codons 195 to the C-terminus (195-CTD; Figure 2.3A) in E. coli plasmid pSU24 and
tested its ability to deaminate cytosines using previously described kanamycin-resistance
reversion assay(313,317). The results are shown in Figure 2.3.
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Figure 2.3. Structure and activity of APOBEC3B constructs. (A) Alignment between parts of
A3G and A3B sequences is shown. The secondary structural elements within A3G (34) are
shown as boxes above the sequences. The amino terminal end of 193-CTD, 195-CTD and 187CTD are indicated by arrows. (B) Results of KanR reversion assay for 195-CTD in the absence of
IPTG in the host BH214. The horizontal lines within the data points represent the median values.
(C) KanR revertants due to 195-CTD following induction of its transcription using 50 µM or 100
µM IPTG. ** represents P value of <0.01. (D) The results of KanR reversion assay for the fulllength A3B and its 193-CTD and 187-CTD constructs in BH214 in the absence of IPTG.
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The 195-CTD was not significantly more mutagenic than the empty vector (Figure 2.3B).
The cloned A3B gene fragment is downstream of both the T7 and -galactosidase promoters in
pSU24(318) and these experiments were performed using a strain that carries the T7 RNA
polymerase gene in its genome. To increase expression of 195-CTD, the cells were grown in the
presence of the inducer IPTG and reversion assays were repeated. This resulted in higher
revertant frequencies, but the 195-CTD was still not highly mutagenic (Figure 2.3C). We
wondered whether making the CTD longer at its amino terminus would increase its activity and
we prepared two additional constructs, 187-CTD and 193-CTD, to test this possibility (Figure
2.3A).

Figure 2.4. Activity of APOBEC3B constructs in BH400. The results of KanR reversion assay
for the full-length A3B and its 193-CTD and 187-CTD constructs in host BH400. The empty
vector serves as the negative control. *** represents P value of <0.001.

Both 187-CTD and 193-CTD constructs were much more mutagenic than 195-CTD even
without IPTG in the growth media (Figure 2.3D). The 193-CTD was slightly less mutagenic than
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187-CTD and both the CTD constructs were somewhat less mutagenic than the full-length A3B
(Figure 2.3D). However, in a different genetic background (BH400 strain) where the kanamycinsensitive allele is located in the bacterial chromosome, both the CTD constructs were more
mutagenic than full-length A3B and 193-CTD was significantly more mutagenic than 187-CTD
(Figure 2.4). Based on these results we conclude that both 187-CTD and 193-CTD are
substantially more mutagenic than the 195-CTD, and are likely to have enzymatic activity which
is comparable to the full-length A3B.
2.3.2 The importance of Met-193 for APOBEC3B enzyme activity
The sequence at the amino terminal end of 193-CTD is MDPDTF, while the 195-CTD has
MPDTF (Figure 2.3A, the underlined Met residue is the initiator methionine). We were surprised
by the results described above which implied that an insertion of a single Asp after the initiator
methionine in the 195-CTD construct had a strong effect on its mutagenicity. To investigate
whether this aspartate plays a critical role in the mutagenicity of A3B, a D194A mutant of fulllength A3B was constructed. However, it was as mutagenic as the wild-type A3B (Figure 2.5A).
The same mutation within the 193-CTD also did not reduce mutagenicity of this gene fragment
(Figure 2.5B). This shows that the Asp-194 residue is not essential for the mutagenic activity of
the CTD.
In contrast, when Met-193 in the full-length A3B was changed to Ala, the KanR revertant
frequency decreased ~28-fold and changing the residue to Glu decreased the mutagenicity
further by a factor of ~4 (Figure 2.6A). Changing Met-193 to Phe had a much more modest
effect on mutagenicity (Figure 2.6A), suggesting that both the size and the hydrophobicity of the
side chain of the residue at this position may be important for the catalytic function of A3B CTD.
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Figure 2.5. KanR reversion assay for D194 APOBEC3B mutants. Effect of D194A mutation
on KanR revertant frequency in (A) full length A3B and (B) 193-CTD. Revertant frequencies due
to WT gene and its catalytically inactive mutant E255A are also shown.
To confirm that the lower mutagenicity of Met-193 mutants in the KanR assay was not due
to changes in sequence selectivity of the enzyme, we performed rifampicin-resistance (RifR)
assay. Rifampicin-resistance is acquired principally as a result of mutations in the rpoB gene in
the chromosome and C to T mutations in many different sequence contexts can create the Rif R
phenotype(319). This assay also showed that the M193A and M193E mutants of full-length A3B
were highly defective in their ability to cause mutations (Figure 2.6B). We also made an
additional construct in which a glycine codon was inserted between the Met-193 and Asp-194
codons in 193-CTD (N-terminal sequence MGDPDTF) and this variant also had substantially
reduced mutagenic activity. For these and other reasons we conclude that Met-193 is required for
full catalytic activity of A3B and its position relative to other amino acids within the protein is
also important for its function.
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Figure 2.6. KanR reversion and RifR mutation assay for M193 APOBEC3B mutants. (A)
Effect of Met-193 mutations on KanR revertant frequency. Revertant frequencies due to Ala, Glu
or Phe mutants are compared to the full length A3B and the E255A. ** represents P value of
<0.01 and *** represents P value of <0.001. (B) Effect of Met-193 mutations on RifR frequency
in BH214. RifR frequencies due to Ala or Glu mutants are compared to the full length A3B and
the E255A.
2.3.3 Purification and characterization of APOBEC3B CTD
A carboxy terminal poly-His tag was added to both the 193-CTD and 187-CTD fragments
of A3B gene, the tagged proteins were expressed in E. coli and purified over two successive
chromatography columns. The proteins appear nearly homogenous in Coomassie Blue stained
gels (Figure 2.7A). However, the yield of the 193-CTD (1.75 mg/L) was about three times higher
than that of 187-CTD. In contrast to these two constructs, 195-CTD expressed poorly in E. coli
and hence no attempt was made to purify it to homogeneity. Due to the lower yield of 187-CTD
and somewhat higher catalytic activity of the 193-CTD (Figure 2.7B), biochemical studies of
only 193-CTD are described below.
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Figure 2.7. Purification and biochemical characterization of A3B-CTD. (A) Image of
Coomassie Blue-stained gels for purified 193-CTD along with the size markers. (B) Comparison
of cytosine deamination ability of 193-CTD and 187-CTD proteins.
The purified 193-CTD was analyzed using time-of-flight matrix-assisted laser desorption
ionization (MALDI-TOF) spectrometry to determine its molecular mass. The protein showed one
strong peak close to its expected molecular mass (23,473.28 Da; Figure 2.8A), confirming that
the protein preparation was quite pure. The size of the purified 193-CTD is consistent with the
initiator methionine being present in the protein.
Interestingly, the mass spectrum for 193-CTD repeatedly showed a second minor peak at
approximately twice the molecular mass of the main peak (Figure 2.8A). Although the intensity
of this peak was very low (about 1% of the intensity of the major peak; Figure 2.68, inset), this
suggested that 193-CTD dimerizes and at least a fraction of the dimers remain intact during the
laser-induced vaporization of the protein.
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Figure 2.8. Properties of purified A3B 193-CTD protein. (A) The MALDI-TOF mass spectra
of purified 193-CTD. The intensity (arbitrary units) is plotted against the m/z ratio. The
molecular weight of the strong peak is marked on the spectrum. Inset- Enlargement of the peak
around 47,000 Da. (B) Chromatography pattern of purified 193-CTD on Superdex-75 column.
The UV absorbance (arbitrary units) is plotted against the Ve/V0 ratio. Positions of different size
standards used to calibrate the column are shown by downward arrows. The observed peaks are
indicated by upward arrows and their calculated molecular weights are shown.
To confirm the dimerization of 193-CTD, the purified protein was rechromatographed on a
pre-calibrated Superdex-75 column. Two distinct peaks were seen in the absorbance profile of
the eluted protein and the elution volumes of the peaks matched roughly with the predicted
monomer and dimer species of 193-CTD (Figure 2.8B). SDS-PAGE analysis of fractions from
both the peaks showed that they contained the same protein and deamination assays showed that
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both peaks contained catalytically active protein. Together these results show that the purified
193-CTD monomer is in thermodynamic equilibrium with its dimeric form. Further experiments
are needed to determine whether the monomer or the dimer is catalytically more active.
2.3.4 Cytosine deamination by APOBEC3B CTD
Purified 193-CTD was further characterized biochemically starting with its stability in
solution. The protein was pre-incubated at 37 C in the reaction buffer for various lengths of time
and then a DNA substrate containing a single cytosine was added to each reaction. The
incubations were continued further for 15 min before they were terminated, the DNA was
cleaved at the uracils and the products were separated on a denaturing gel as described
previously(10). The results from two independent experiments showed that the enzyme was
stable for at least the first 15 minutes of pre-incubation (Figure 2.9A). Additional preliminary
experiments also showed that the enzyme was able to create more product than its molar amounti.e. “turn over” (Figure 2.9B).

A

B

Figure 2.9. Preliminary characterization of purified APOBEC3B 193-CTD. (A) Stability of
193-CTD during reaction incubations. The ability of 193-CTD protein to convert cytosine to
uracil is quantified following pre-incubations for different lengths of time. (B) Ability of 193CTD to turnover. The amount of product generated by the enzyme is shown under two different
ratios of substrate to enzyme.
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Based on these results we designed experiments to determine the kinetic parameters of the
enzyme using three different oligomeric substrates (Table 2.2). The vmax and KM for the three
DNA substrates were roughly similar. However, the apparent KM of the enzyme (37 to 74 M)
was about the same or higher than the highest substrate concentration used in biochemical assays
(40 M). Additionally, as the protein exists in both monomeric and dimeric forms, the
concentration of the catalytically active form of the enzyme is unknown. Consequently the
catalytic efficiency of the enzyme is reported only as apparent vmax/KM in Table 2.3. This number
was similar for the three substrates and is quite low (Table 2.3). These results suggest that the
193-CTD purified from E. coli is a slow enzyme and the nucleotide 3’ to the target cytosine does
not have a strong effect on enzyme activity.
Table 2.3. Kinetic Parameters of APOBEC3B 193-CTD
Name

Oligomer

Sequence

Total protein

Apparent

Apparent

size

context

concentration*

KM

vmax/ KM

(M)

(M)

(min-1)

(nt)
TCGA-40

40

ATCGA

0.20

73.9

8.9x10-3

TCAG-30

30

ATCAG

0.13

47.8

9.1x10-3

TCGG-30

30

ATCGG

0.13

37.3

8.3x10-3

* The protein is assumed to be monomeric. nt- nucleotides.
As shown above, the full-length A3B has higher mutagenicity than the CTD in at least one
genetic background (Figure 2.3D) and hence we wondered whether the NTD enhances the
catalytic activity of the CTD. When we attempted to test this by cloning the full-length gene in
an expression plasmid, all the clones were found to contain missense mutations. Fourteen
independent clones were examined and they contained base substitutions, insertion/deletions or
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both. In each case the mutation(s) changed the amino acid sequence of A3B CTD. We conclude
that full-length A3B is toxic to E. coli due to its high mutagenicity (Figure 2.3D) and this leads
to selection of mutant variants. For this reason, the full-length protein was not purified and
instead we examined the mutagenicity of A3B NTD in E. coli and the ability of A3B NTD
protein to deaminate cytosines on its own and in cooperation with 193-CTD.
2.3.5 Genetic and biochemical characterization of the APOBEC3B NTD
The ability of A3B NTD (residues 1 through 192) to deaminate cytosines was judged using
both genetic and biochemical assays. In the KanR reversion assay, the NTD increased the
revertant frequency above the frequency obtained with empty vector by a small amount, but the
increase was not statistically significant (Figure 2.10A). These results are consistent with
previous reports of low mutational activity of the NTD in rifampicin-resistance assay(249). This
suggests that the A3B NTD is at best a weak deaminase on its own and we confirmed this by
characterizing partially purified NTD.
An amino-terminal poly-His tag was attached to the NTD (residues 1 through 192), the
tagged protein was expressed in E. coli and purified over a Ni2+ affinity column. Although its
expression was not as high as 187-CTD or 193-CTD, Coomassie Blue staining showed a
prominent band at the expected size. The concentration of the NTD in the preparation was
estimated based on BSA standards and used for in vitro deamination assays.
When TCGA-40 DNA substrate was incubated with excess A3B NTD, no deamination
product was detected (lanes 4, 6 and 8, respectively; Figure 2.10B). Furthermore, the NTD did
not enhance the deamination activity of 193-CTD when the DNA was co-incubated with the two
proteins (lanes 5, 7 and 9; Figure 2.10B). These results suggest that A3B NTD has little intrinsic
deamination activity, and it does not enhance the catalytic activity of the CTD in trans.
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A

B

Figure 2.10. Inability of APOBEC3B NTD to deaminate cytosines. (A) KanR reversion assay
for A3B NTD. The revertant frequencies due to the NTD are compared to full length A3B and
the empty vector. (B) Lack of cytosine deamination activity for partially purified NTD. The
TCGA-40 substrate (2 pmol) was incubated with different amounts of the NTD alone (lanes 4, 6
and 8 respectively) or together with 10 pmol of 193-CTD (lanes 5, 7 and 9).
2.3.6 5-Methylcytosine deamination activity of APOBEC3B CTD
The ability of 187-CTD and 193-CTD constructs to deaminate 5-methylcytosine (5mC) was
tested using the KanR reversion assay in the E. coli strain BH400 which also contained the gene
for a cytosine methylase, Dcm, on a compatible plasmid(10). In this strain, Uracil-DNA
glycosylase (Ung) repairs all the uracils in DNA and only a 5mC to T deamination creates KanR
revertants(10). A3A, which is an efficient deaminase of 5mC(10,198,199), served as the positive
control in these experiments and the data are presented in Figure 2.11.
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Figure 2.11. Ability of APOBEC3B to deaminate 5-methylcytosines. Comparison of KanR
revertant frequencies due to conversion of 5mC to T. The abilities of 193-CTD, 187-CTD and
full length A3B to deaminate 5mC are compared with empty vector and A3A. ** represents P
value of <0.01 and *** represents P value of <0.001.
The full-length A3B, 187-CTD and 193-CTD caused a significant increase in the KanR
revertant frequency in this genetic background and the CTD constructs displayed higher
mutagenicity than the full-length A3B (Figure 2.11). However, the revertant frequencies due to
the A3B constructs were about ten-fold lower than those due to A3A (Figure 2.11). This suggests
that although A3B is capable of 5mC deamination, it may not be as efficient as A3A in this
reaction.
The ability of the purified 193-CTD protein to deaminate 5mC was tested using two
different DNA substrates (Table 2.2) and this was compared with its ability to deaminate
cytosine in the same sequence context. The 193-CTD did convert some 5mC in each substrate to
T, but this was much less efficient than its ability to convert C to U (Figure 2.12A). When the
maximum reaction velocity was calculated for TMAG and TMGG substrates (M is 5mC), the
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specific activity of 193-CTD was respectively about 25-fold and 11-fold (average 16-fold) lower
for the 5mC-containing oligomers than the corresponding C-containing substrates. For
comparison, A3A protein was partially purified and was used in deamination assays with TCGG
and TMGG oligomers as substrates. The enzyme was about five times more efficient at
deaminating C than 5mC (Figure 2.12B). The more modest preference of A3A for the
unmodified cytosine has been noted before(10), and the data presented above suggest that A3B
has a stronger preference for C over 5mC than A3A.

A

B

Figure 2.12. Kinetics of cytosine and 5mC deamination. (A) Comparison of kinetics of
cytosine and 5mC deamination by 193-CTD. DNA oligomers containing a single C or 5mC in
the indicated sequence context were treated with increasing concentrations of purified 193-CTD
and the products were quantified. (B) Kinetics of cytosine and 5mC deamination by partially
purified A3A.
2.4 Discussion
Using deletion constructs and point mutations, we defined the catalytic domain of the
human APOBEC3B gene. The maximally active domain spans from Met-193 to the carboxyterminal end of the protein (193-CTD). This domain was somewhat less mutagenic than the fulllength A3B. The purified 193-CTD protein was active in vitro and was used to determine the
kinetic parameters for deamination of cytosines and 5-methylcytosines in single-stranded DNA.
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These studies show that the bacterially purified protein is a slow enzyme with a strong
preference for deaminating C compared to 5mC. We also analyzed the purified 193-CTD by
MALDI-TOF and size exclusion chromatography and found that the carboxy-terminal domain
dimerizes. This raises the possibility that this interaction may also occur in full-length A3B
resulting in its dimerization. These studies also show that Met-193 residue is required for the
optimal mutational activity of the full-length A3B.
The previously characterized version of A3B CTD that starts at residue 195(270,309) is only
weakly active (Figure 2.3B and 2.3C) and 193-CTD is more mutagenic than 195-CTD by at least
a factor of ten (Figure 2.3B and 2.3D). Additionally, we found that replacing Asp-194 with Ala
did not decrease its mutagenicity (Figure 2.5A and 2.5B). In contrast, while Met to Glu
substitution at position 193 reduced mutagenicity of full-length A3B by two orders of magnitude,
a Met to Phe substitution had a much more modest effect (Figure 2.6A and 2.6B).
These mutational studies led us to examine the role of this methionine in A3B structure and
whether it is conserved in the AID/APOBEC family of proteins. We first aligned A3B CTD
sequence with the sequences of these enzymes using Clustal Omega software(315) and manually
adjusted it to conserve secondary structure elements found within 3D structures of CTDs of two
double-domain APOBEC3 proteins (A3F and A3G) and complete structures of two singledomain APOBEC3 proteins (A3A and A3C)(24,28,30-32,35). The alignment suggests that Met193 is conserved among these cytosine deaminases (Figure 2.13). We note that while some
investigators have previously suggested the same alignment for Met-193 of A3B shown in
Figure 2.11(213,237,320), others have aligned Met-193 with different residues in other
APOBEC3s(308,321).
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Figure 2.13. Sequence alignment of APOBEC3B CTD and APOBEC3 proteins with known
structures. Clustal Omega alignment of APOBEC3 single domain proteins (A3A and A3C),
CTD of two domain proteins (A3F and A3G) with A3B CTD is shown. The structural motifs are
shown according the structure of A3G CTD (34). The conserved methionine at the junction of
NTD and CTD is marked with a green arrow. All the conserved residues between the five
proteins are shown in blue and marked by asterisks. The residues that line the hydrophobic
pocket in which the conserved methionine resides are shown in red and are marked with a dot.
Mutational studies of other members of this family are consistent with this alignment. In
particular, alanine-scanning mutagenesis of the NTD-CTD junction in A3G(34) found that
among the 20 residues mutated only mutations at Met-197, Phe-202, Phe-206 and Asn-208
eliminated mutator phenotype of A3G in E. coli(308). Furthermore, larger hydrophobic
substitutions at Met-197 position such as Cys and Phe did not eliminate mutagenicity(322).

73
Mutational analysis of APOBEC3A has shown that while the first methionine in APOBEC3A is
dispensible for its activity, the methionine aligned with Met-193 of A3B(Figure 2.13; Met-13) is
essential for the deamination activity of the protein(323). Similar mutational analysis of AID has
also shown that the methionine that aligns with Met-197 of A3G, Met-6, is essential for its
activity(324).
Examination of the known APOBEC3 family 3D structures points to a structural role for
this conserved methionine. All the structures show that the conserved methionine side chain is
inserted into a hydrophobic pocket formed mainly by phenylalanines and cysteines (Figures. 2.13
and 2.14). For example, A3G CTD structure (PDB: 3IR2) shows that this pocket is created by
residues from helices 1 and 5, and strands 1, 2’ and 3 (Figures. 2.12 and 2.14). In A3G
CTD the Met-197 residue is sandwiched between walls formed by Phe-202 and Phe-206 on one
side, and Phe-241 and the phenolic ring of Tyr-219 on the other side. Phe-350 and Cys-346 form
the floor of this pocket (Figure 2.14A). Representation of this region of A3G based on
hydrophobicity shows that the hydrophobic pocket is close to the protein surface and is strongly
hydrophobic on one side (orange) and less so on the other side. The terminal methyl group in
Met-197 is inserted into the pocket and points the terminal methyl group towards Phe-282 and
Cys-221 (Figure 2.14B). As noted above, Harjes et al(34) found that substitution of Phe-202 or
Phe-206 with Ala eliminated mutagenicity of A3G. This shows that the high hydrophobicity of
this pocket is required for enzyme activity. The pocket is quite large and hence the replacement
of Met-197 with the larger Phe side chain is conservative. However, the pocket is too large for
the smaller Ala side chain explaining the lack of activity for the M197A mutant of A3G (34).
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C

Figure 2.14. Structure of the hydrophobic pocket in different APOBEC3 proteins.
(A) Structure of the hydrophobic pocket in which A3G Met-197 resides (based on PDB entry
3IR2). Met-197 is shown in purple and yellow (sulfur), other side chains are shown in grey
(carbon) and red (oxygen). Active site zinc ion is labeled as Zn1 and is coordinated to two
cysteines and one histidine. Helices 1 and 5, and beta strands 1, 2’ and 3 are marked. (B)
Representation of the pocket in which A3G Met-197 resides based on hydrophobicity. Met-197
side chain is shown as a grey stick with sulfur in yellow. The hydrophobicity scale goes from
red-orange (hydrophobic) to Dodger blue (polar) with white in the middle. (B) Representation of
the pocket in which the conserved methionine resides in A3A (PDB: 2M65), A3C (3VOW) and
A3F (4IOU) structures based on hydrophobicity. Same color scheme as part B. For A3A
structure all the NMR conformers are shown.
The structures of other APOBEC3 family members confirm the existence of this deep
hydrophobic pocket and show that a majority of the residues lining the pocket are conserved
among the APOBEC3s (Figure 2.13 and 2.14C). Since there was no crystal structure available
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for A3B during this study, we created a 3D structure for A3B 193-CTD using homology
modeling, and this structure also showed Met-193 to be similarly inserted in a hydrophobic
pocket (Figure 2.15). Together these results show that the conserved methionine at the junction
of NTD and CTD domains of two domain APOBEC3s and near the amino terminus of single
domain APOBEC3s (Figure 2.13) acts as the “glue” that holds together two  helices and three 
strands and is essential for the structural stability of these enzymes.

Figure 2.15. Homology model of the Met-193 of APOBEC3B in a hydrophobic pocket. The
methionine side chain is shown in the stick configure with carbons (brown) and sulfur (yellow).
The pocket is shown using the hydrophobicity module in UCSF Chimera (39) and the residues
forming the pocket are labeled. The hydrophobicity scale goes from red-orange (hydrophobic) to
Dodger blue (polar) with white in the middle.
Currently there are several crystal and NMR structures available for A3B. Among them
there are crystal structures of CTD (PDB: 5CQI(29) and 5SXG(325)), a variant of CTD
complexed with ssDNA (PDB: 5TD5(26)), NMR structure of CTD (PDB: 2NBQ(326)) and a
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crystal structure of NTD (PDB: 5TKM(327)). The A3B-CTD construct used for crystallization
(A3B (187-378)QM_Δloop3) has 4 amino acid substitutions (F200S, W228S, L230K, F308K)
and a truncation of the flexible loop 3(29) to improve solubility of the protein.

A

B

C

Figure 2.16. Hydrophobic pocket in the crystal structure of A3B. (A) Superposition of A3B
(187-378)QM_Δloop3 crystal structure (PDB: 5CQI, orange) with modeled 193-CTD (cyan).
M-193 and the residues forming the hydrophobic pocket in (B) crystal structure and (C) modeled
structure of A3B-CTD.
Superposition of this crystal structure with our modeled 193-CTD structure shows high
overall similarity with a RMSD (root-mean-square deviation) of 1.767 Å (Figure 2.16A). The
crystal structure also shows insertion of Met-193 in a hydrophobic pocket similar to the modeled
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structure (Figures 2.16B and 2.16C). These observations further confirms the accuracy of our
predicted hydrophobic pocket surrounding the M-193 in A3B.
Another structural insight from this work is that 193-CTD dimerizes and the dimers are
stable enough that a fraction of them survive laser-induced vaporization (Figure 2.8A and 2.8B).
It is likely that full-length A3B also dimerizes using the same interactions and this may explain
the in vivo multimerization of highly expressed A3B reported recently(54). It is well-known that
A3G

oligomerizes(56,58,308,328,329)

and

this

ability is

related

to

its

biological

function(53,56,59,62,255). Head-to-head and head-to-tail dimers as well as higher order
oligomers of A3G have been proposed based on physical studies and it will be interesting to
determine the type of multimeric structures A3B can form and the relationship of such structures
with the biological function of A3B.
An important conclusion from this study is that A3B is much less efficient at deaminating
5mC compared to C. In particular, full-length A3B as well as the 187-CTD and 193-CTD
constructs were much less mutagenic at a methylated cytosine in DNA in an E. coli genetic assay
than A3A (Figure 2.11). Furthermore, biochemical assays showed that the purified 193-CTD was
on average 16-fold weaker at 5mC deamination in different DNA substrates compared to C
(Figure 2.12A). Other members of AID/APOBEC family also show a preference for
unmethylated cytosines. While we find that A3A has only a four(10) to five-fold preference (this
study) for the unmethylated substrate over 5mC, another group reported a 10-fold selectivity for
C(198). AID also prefers C over 5mC by a factor of about 10(4,10,126,127). Thus, A3B appears
to disfavor 5mC over C at least as much as the other characterized members of the
AID/APOBEC family and may be more biased against 5mC bases in this regard than A3A.
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The poor ability of A3B at deaminating 5mC has implications to the possible role of A3B in
causing DNA demethylation and genomic mutations. The AID/APOBEC family of enzymes
have been widely proposed to play a role in DNA demethylation through a deamination and base
excision repair-based mechanism(183,330-332). Recent work has also shown that many of the
mutations found in a variety of cancer genomes bear the signature of mutations caused by
members of the AID/APOBEC family(265,268,270,333). While the signatures 2 and 13 which
contain C to T and C to G mutations in TCX context (X is any base) have been suggested to be
due to deamination by the APOBEC family members(268), other signatures may also be linked
to these enzymes. In principle, most commonly found mutations, C to T substitutions at XpCpG
(signatures, 1A and 1B) could be attributed to deamination of 5mC residues in CpGs by
APOBEC family members. Additionally, signatures 6, 7, 11, 15 and 19 also predominantly
contain C to T mutations but they are in both CpG and non-CpG contexts(268). Based on our
results using bacterial genetic assays and using protein purified from E. coli, we conclude that
A3B is much more efficient at deaminating C compared to 5mC and this makes it less likely that
it plays a major role in DNA demethylation or causing mutations at methylated CpG sites in the
human genome.
Our results also suggest that the full-length A3B is more mutagenic than A3B CTD and is
toxic to E. coli. Although these genetic results did not clearly establish how the A3B NTD
affects catalytic activity of A3B CTD, they did suggest the A3B NTD may affect the function of
the CTD. However, genetic studies of the NTD did not show a mutator phenotype and
biochemical studies with partially purified NTD showed that the NTD had no detectable catalytic
activity and did not significantly enhance or inhibit the ability of the 193-CTD to deaminate
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cytosines in trans (Figure 2.10B). It is still possible that the NTD can enhance the catalytic
activity of the CTD in cis; i.e. when the two domains are covalently attached to each other.
In summary, we have used genetic and biochemical tools to define the catalytic domain of
human A3B protein and identified a novel structural role of a methionine at the junction of its
NTD and CTD. We have determined the kinetic parameters of this catalytic domain and also
showed that it is a poor deaminase of 5-methylcytosines. We have further shown that the A3B
CTD self-dimerizes, and that A3B NTD has little intrinsic ability to deaminate cytosines. These
observations clarify the structural organization of the APOBEC3 family of mutators and suggest
that A3B is unlikely to play a role as a major mutator of methylated cytosines or as the first
enzyme in a demethylation pathway.
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CHAPTER 3: A TUMOR PROMOTING PHORBOL ESTER CAUSES A LARGE
INCREASE IN APOBEC3A EXPRESSION IN NORMAL HUMAN KERATINOCYTES
WITHOUT INCREASING GENOMIC URACILS
3.1 Introduction
Phorbol 12-myristate 13-acetate (PMA; also called 12-O-tetradecanoylphorbol-13-acetate
or TPA) causes inflammatory response in skin cells and promotes tumors. In the two stage
murine skin carcinogenesis protocol, a single application of sub-carcinogenic dose of the
mutagen 7,12 dimethylbenz[a]anthracene (DMBA) followed by repeated application of PMA
causes tumors(17). PMA is an analog of diacylglycerol (DAG) and has the ability to bind and
strongly activate protein kinase C (PKC) which regulates signal transduction pathways through
the activation of NF-κB(334,335). The binding of PMA to PKC leads to prolonged activation of
PKC resulting in synthesis of many pro-inflammatory cytokines such as TNF-α and growth
factors. In keratinocytes this results in cell proliferation, increased production of reactive oxygen
species (ROS) and inflammation(336-338). The ability of PMA to cause persistent inflammation
and oxidative stress are thought to contribute to its function as a tumor promoter(339).

Figure 3.1. PMA induce APOBEC expression via PKC/NF-κB pathway. Activation of PKC
by PMA leads to increased APOBEC expression through NF-κB pathway.
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PMA is known to induce the expression of some members of the human APOBEC3
subfamily of DNA-cytosine deaminases. These seven enzymes (APOBEC3A, APOBEC3B,
APOBEC3C, APOBEC3D/E, APOBEC3F, APOBEC3G and APOBEC3H) belong to the
AID/APOBEC family and convert cytosines in single-stranded DNA (ssDNA) to uracil (340)
The processing of these uracils can either restore the original C:G base pair or cause genome
instability through the introduction of mutations, abasic sites and strand breaks (209). The first
member of this subfamily to be described, APOBEC3A (A3A), was initially found as a protein
that is overexpressed when human skin keratinocytes were treated with PMA, and was named
phorbolin-1(185). Elevated levels of A3A were also seen in skin inflammation conditions such as
psoriasis and acne (185,341).
The main biological function of APOBEC3 subfamily of proteins is to provide innate
immunity against viral infection and inhibit retrotransposition of endogenous retroelements by
causing mutations and strand breaks(66,340). Recently, APOBEC3 mutational signature was
observed in multiple human cancers suggesting that these enzymes may play a role in tumor
evolution(342,343)and perhaps tumorigenesis(265,268,333). While APOBEC3B (A3B) has been
described

as

the

major

cancer

genome

mutator

among

the

APOBEC3

proteins(269,270,309,344,345), A3A has also been implicated in cancer genome mutations in
several studies(271,272). However, the impact of A3A protein on genome integrity may depend
on the cell type and the mode of A3A expression. In monocyte cells, the endogenously expressed
A3A is cytoplasmic and does not cause any significant genotoxicity as measured through cell
viability(196). In contrast, several studies have shown that stably or transiently transfected A3A
is present in the nuclei, causes mutations, strand breaks and disrupts the cell cycle(277,346-349).
Therefore, the expression of A3A in keratinocyte cells in response to PMA treatment has the
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potential of causing genome instability and promote carcinogenesis, if it is transported to the
nuclei.
To test this possibility, we treated a normal human oral keratinocyte cell line with PMA
and confirmed the expression and nuclear localization of A3A. Surprisingly, the presence of
A3A in the nucleus did not result in an increase in genomic uracil levels. We describe below the
biochemical and biological response of this cell line to PMA treatment in the context of
AID/APOBEC proteins, and provide a possible explanation for why the nuclear A3A is not
genotoxic to these cells.
3.2 Materials and methods
3.2.1 Treatment of cells with different chemicals/cytokines
A total of 1 x 106 cells were plated in T25 cell culture flasks 1 day prior to
chemical/cytokine treatment . 25 ng/ml of phorbol 12-myristate 13-acetate/PMA (Sigma) alone
or in combination with 10 ng/ml TNF-α (STEMCELL Technologies) was then added to the
media and incubated at 37°C with 5% CO2 for 24 hours until the cells were harvested for RNA,
DNA or protein extraction. Treatment of MCF-10A cells was carried out only for 6 hours.
3.2.2 Cell lines and culture conditions
Immortalized normal human oral keratinocyte cell line (NOK) prepared from gingival
tissues obtained from oral surgeries was a kind gift from Dr. Karl Munger (Harvard Medical
School). Cells were cultured in serum-free medium (Keratinocyte-SFM; Life technologies)
supplemented with epidermal growth factor and bovine pituitary extract. Human cell lines
HEK293T (immortalized embryonic kidney) and MCF-10A (breast epithelial) were obtained
from American Type Culture Collection (ATCC) and primary human epidermal keratinocytes
(HEKn) was obtained from Thermo-Fisher. The epidermoid carcinoma cell line A431 was kindly
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provided by Dr. Young-Hoon Ahn (Wayne State University). HEK293T and A431 cells were
cultured in DMEM medium (HyClone) with 10% FBS and 1% Pen-Strep (Hyclone). MCF-10A
cells were grown in HuMEC Basal Serum-Free Medium (Gibco) with HuMEC Supplement Kit
and 100 ng/ml Cholera toxin (Sigma). HEKn cells were grown in EpiLife® medium (Gibco)
supplemented with EDGS and 1% Pen-Strep. All cultures were incubated at 37°C in a
humidified incubator with 5% CO2 in T-25 cm2 or T-75 cm2 flasks; or 24-well plates (CytoOne,
USA scientific). All the cell lines were used within 12 months of their validation.
3.2.3 RNA extraction and quantitative Reverse-Transcription PCR (qRT-PCR)
Total RNA was extracted from cells using Trizol reagent (Invitrogen) according to
manufacturer’s instructions. Reverse transcription of RNA was carried out using oligo-d(T)23
primers and the ProtoScript® II First Strand cDNA Synthesis Kit (New England Biolabs). To
determine expression level of AID/APOBEC3, human TNF-α and UNG genes relative to TBP,
cDNA were amplified using primers previously published(270) or listed in Table 3.1 and
PowerUP SYBR Green Mix (Applied Biosystems). The amplification was performed using an
Applied Biosystems 7500 fast real-time PCR system. Data were analyzed using ∆∆Ct method.
Table 3.1. Primers for qRT-PCR
Gene

qRT-PCR 5' primer sequence

qRT-PCR 3' primer sequence

Human
TNF-α

5' GGAGAAGGGTGACCGACTCA

5' CTGCCCAGACTCGGCAA

Human
UNG2

5' CCTCCTCAGCTCCAGGATGA

5' TCGCTTCCTGGCGGG

5' CCCCACACCAAGTCTTCACC

5' TTGAACACTAAAGCAGAGCCC

Human
UNG (1 & 2)
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3.2.4 Genomic DNA isolation
The cells were harvested by centrifugation and lysed by incubation for 1hr at 37°C in
Tris-EDTA buffer (TE) containing 2 μg/ml of RNase A and 0.5% SDS, followed by incubation
with Proteinase K (100 μg /ml, Qiagen) at 56°C for 3 hours. The DNA was isolated by
phenol/chloroform extraction and ethanol precipitation, and dissolved in TE.
3.2.5 Quantification of genomic uracils
To quantify the total uracils in the genomic DNA, a Uracil quantification assay developed
by Bhagwat group modified using AA6 based Cu free click chemistry was used(350). An outline
of the assay is schematically represented in Figure 3.11. Briefly, digested genomic DNA was
incubated with methoxyamine (Fisher Scientific, 10 mM final concentration) to block the
endogenous abasic sites. The DNA was then treated with E. coli uracil DNA-glycosylase (UNG,
New England Biolabs) and 2 mM AA6. UNG removes uracils and AA6 labels the resulting AP
sites that remain after uracil excision. AA6 tagged DNA was labeled with DBCO-Cy5 (1.7 mM)
under Cu free conditions by shaking the reaction mixture for 2 hours at 37°C. Labeled DNA was
purified using DNA clean and concentrator kit (Zymo research). DBCO-Cy5 labeled DNA was
transferred on to a positively charged zeta probe membrane (Bio Rad) and the membrane was
scanned using a Typhoon 9210 phosphor imager (GE Healthcare). Images were analyzed using
the ImageQuant software.
3.2.6 Western blot analysis
Whole cell extracts were prepared by incubating the cells in lysis buffer (50 mM TrisHCl, 150 mM NaCl, pH 7.4, 1% Triton X-100, 1x Halt protease inhibitor cocktail) for 1 hour at
4°C and centrifuging at 12,000 g for 10 min to clarify the lysate. The total protein concentration
was measured using Bio-Rad protein assay dye reagent concentrate (Bio-Rad). Protein samples
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(30-50 µg) were subjected to 15% SDS-PAGE and transferred to Immobilon-P PVDF
membranes (Millipore).The membranes were blocked with 5% (w/v) nonfat milk and probed
with rabbit Anti-human APOBEC3B monoclonal antibody(187) (kind gift from Dr. R. Harris,
1:1000), rabbit Anti-UNG polyclonal antibody (Abcam, 1:1000), rabbit Anti-β actin
monoclonal antibody (Cell signaling technology, 1:1000) and mouse Anti- α tubulin
monoclonal antibody

at

4°C

overnight.

Protein

levels

were

then

visualized

by

chemiluminescence using appropriate HRP-conjugated secondary antibodies (Cell signaling
technology, 1:1000).
3.2.7 In vitro cytosine deamination or uracil excision assays
For cytosine deamination assay, nuclear and cytoplasmic proteins were extracted from
cells using NucBusterTM protein extraction kit (Millipore) and the protein concentrations were
measured using Bio-Rad protein assay dye reagent. The deamination assay with 3 µg of protein
and 2 pmol of ssDNA containing a single cytosine (5' ATTATTATTATTATCGATTTATTTAT
TTATTTATTTATTT-(6-FAM)) was performed in the reaction buffer [20 mM Tris–HCl (pH
8.0), 1 mM EDTA and 1 mM DTT] for 1 hour at 37°C. The reactions were terminated by heating
them to 95°C for 10 min. 5 units of E. coli Ung (New England Biolabs) were added to the
reaction and incubation was continued at 37°C for 30 min. The reactions were stopped by adding
NaOH to 0.1 M and heating to 95°C for 10 min. The reaction products were separated on a 15%
denaturing acrylamide gel and visualized using Typhoon 9210 phosphorimager (GE Healthcare).
ImageJ software was used to quantify the intensities of the substrates and the deamination
products.
For uracil excision assay, whole cell extracts were prepared as described in a section
3.2.6 and 3 µg of protein was incubated with 2 pmol of ssDNA containing a single uracil (5'
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ATTATTATTATTATUGATTTATTTATTTATTTATTTATTT-(6-FAM)) for 1 hour at 37°C.
In some reactions, UGI (New England Biolabs) was added to the cell lysate to inhibit UNG prior
to incubation with the substrate. The reactions were stopped by adding NaOH to 0.1 M and
heating to 95°C for 10 min. The products were processed and analyzed in a similar way as the C
deamination reactions.
3.2.8 Transfection studies
WT or UNG∆/∆ NOK cells (1x106) were transiently transfected with pEGFP-N3-A3A, an
A3A expression vector (kind gift from Dr. R. Harris and previously described(195)) or empty
vector (pEGFP-N3) using Xfect transfection reagent (Clontec) according to manufacturer’s
instructions. After 24 hours GFP fluorescence was checked to confirm efficient transfection. The
cells were harvested for DNA extraction and uracil quantification.
3.2.9 Cell viability assay
A total of 1 x 105 cells (0.5 x 105 cells for longer experiments) of WT and UNG∆/∆ NOK
were seeded in 24 well tissue culture plates. The following day, cells were treated with PMA,
PMA and TNF-α or transfected with A3A expressing plasmid. Cells were harvested by
trypsinization at different time points. The viability and total number of cells were determined by
the trypan blue exclusion assay using TC20 automated cell counter (BioRad).
3.2.10 Visualization of A3A by immunofluorescence
NOK cells were seeded in Millicell® EZ SLIDES at ~20,000 cells/chamber. The
following day, cells were treated with PMA or PMA and TNF-α. After 24 hours cells were
washed with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. Cells
were then permeabilized with 0.3% Triton X-100 in PBS and blocked with 10% goat serum for 1
hour.
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primary antibody,
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Anti-human

APOBEC3B
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monoclonal antibody (187)(kind gift from Dr. R.Harris, 1:200) following goat anti rabbit
secondary antibody conjugated with Cy3 (Thermo fisher, 1:2000). Coverslips were mounted
onto the slide using ProLong® Gold Antifade Mountant with DAPI (Invitrogen) and visualized
using a fluorescence microscope (Nikon E800) in Department of Microbiology, Immunology and
Biochemistry at Wayne State University, School of Medicine or confocal microscope (Zeiss
LSM 780) in Microscopy, Imaging and Cytometry Resources Core at Wayne State University,
School of Medicine
3.2.11 Generation of UNG-/- NOK cell line using CRISPR Cas9
Two guide RNAs were designed using CRISPR DESIGN (http://crispr.mit.edu/) tool to
delete part of exon 2, entire exon 3 and part of exon 4 of Ung gene (Accession No NG_ 007284)
in NOK cells. The oligonucleotides used are listed in Table 3.2. Annealed oligonucleotides were
cloned into pSpCas9(BB)-2A-GFP vector (kind gift from Dr. Kefei Yu) and verified by
sequencing. Both cloned vectors were transfected into NOK cells using Xfect transfection
reagent. After 48 hours, GFP positive cells were sorted by FACS (Microscopy, Imaging and
Cytometry Resources Core at Wayne State University, School of Medicine) and single cells were
seeded in a 96 well plate. DNA were extracted from single cell subclones using QuickExtract™
DNA extraction solution (Epicentre) for PCR screening using primers specific for a region of
UNG gene (forward primer 5' TGTTCCACAAATGGGCGTCT and reverse primer 5'
CTGCAGTCACCTGTAAAGCAAC). Positive clones with successful gene deletion were
further confirmed by sanger sequencing, qRT-PCR for mRNA expression, western blot for UNG
protein expression and activity assay for uracil excision ability.
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Table 3.2. Oligonucleotides used in generating UNG knock out NOK cells using CRISPR/Cas9

Exon

Target
(5'-3')

2

GCGGCCCGCAACG
TGCCCGT

4

GCTTGATTAGGTCC
ATGATA

PAM

Top gRNA oligo
(5'-3')

Bottom gRNA oligo
(5'-3')

GGG

CACCGCGGCCCGCAA
CGTGCCCGT

AAACACGGGCACGTTG
CGGGCCGC

CACCGCTTGATTAGG
TCCATGATA

AAACTATCATGGACCT
AATCAAGC

TGG

3.3 Results
3.3.1 Effects of PMA treatment on AID/APOBEC3 gene expression
Normal oral keratinocyte (NOK) cells were treated with PMA and the changes in the
expression of AID and APOBEC3 genes was determined using qRT-PCR. The AID/APOBEC
genes could be divided into three groups based on the effects of PMA treatment on their
expression. A3C was the most expressed of all the eight genes in untreated NOK cells and its
expression decreased slightly following PMA treatment (Figure 3.2). In contrast, AID, A3D,
A3F, A3G and A3H genes were expressed at very low levels in the untreated cells and these
levels did not significantly increase in response to PMA treatment (Figure 3.2). The A3A and
A3B genes were the only genes whose expression increased substantially following PMA
treatment with the A3A expression increasing from undetectable levels to greater than twice the
level of A3B expression (Figure 3.2).
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Figure 3.2. Effects of PMA treatment on AID/APOBEC3 mRNA expression in NOK cells.
qRT-PCR for mRNA expression of AID/APOBEC3s relative to TBP in NOK cells treated with
25 ng/ml PMA for 24 hours. Mean and SD are shown for triplicate qRT-PCR reactions. * not
detected
This confirms the previous reports that PMA treatment of normal keratinocytes increases
A3A expression (184,185) and extends it to the A3B gene. To determine whether the parallel
increases in A3A and A3B gene expression following PMA treatment reflected some form of
coordinated regulation of the two genes that would be common to other human cells, we tested
the effects of PMA treatment in four other cell lines (Figure 3.3).
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A

Figure 3.3. Effects of PMA treatment on A3A and A3B mRNA expression in different
human cell lines. A3A and A3B mRNA expression relative to TBP after treatment with PMA
for 24 hours in HEKn (primary human epidermal keratinocytes), A431 (epidermoid carcinoma)
and HEK293T (immortalized embryonic kidney) cells and for 6 hours in MCF10A (breast
epithelial) cells. Mean and SD are shown for triplicate qRT-PCR reactions. * not detected
None of the cells tested expressed gene A3A at high levels with or without PMA
treatment. This included two skin-derived cell lines, primary human neonatal keratinocyte cells
(HEKn) and squamous cell carcinoma-derived cell line A431 (Figure 3.3). In contrast, A3B
expression increased upon PMA treatment in three of the four cell types; HEKn, A431 and
MCF10A (Figure 3.3). The increased expression of A3B gene following PMA treatment in
MCF10A cells has been reported before(187) . These results show that different types of primary
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and immortalized human cells have widely different responses to PMA treatment in terms of
A3A and A3B gene expression.

A

B

Figure 3.4. Optimization of APOBEC3A upregulation by PMA. (A) Dose responsiveness of
A3A mRNA upregulation by PMA measured by qRT-PCR in treated NOK cells after 24 hours.
(B) Time-dependant change in A3A mRNA expression with 25 ng/ml PMA. Mean and SD are
shown for triplicate qRT-PCR reactions.
We optimized the expression of A3A in response to PMA treatment by varying the
concentration of the phorbol ester, the length of treatment and combining it with cytokines. We
found that the expression of A3A in NOK cells peaked at 25 ng/mL (Figure 3.4A) around 12
hours post-treatment (Figure 3.4B). We also found that the treatment of cells with PMA caused
an increase in the expression of TNF- (Figure 3.5A) and hence speculated that this cytokine
may contribute to the increases in A3A/A3B expression. To test this, NOK cells were treated
with a cocktail of PMA and TNF-, and the expression of AID/APOBEC genes were monitored.
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Figure 3.5. Effect of TNF-α on APOBEC3A expression. (A) PMA treatment enhances the
expression of TNF-α. TNF-α mRNA expression level measured by qRT-PCR relative to TBP in
NOK cells treated with 25 ng/ml PMA for 24 hours. (B) qRT-PCR for mRNA expression of
A3A relative to TBP in NOK cells treated with 10 ng/ml TNF-α alone, 25 ng/ml PMA alone or
combination of both PMA and TNF-α for 24 hours. Mean and SD are shown for triplicate qRTPCR reactions.
Consistent with the hypothesis, combined treatment of NOK cells with PMA and TNF-
doubled the expression of A3A and slightly increased A3B expression compared to treatment
with PMA alone (Figures 3.5B and 3.6). Combining PMA with TNF- did not cause an increase
in the expression of the other A3 genes or AID (Figure 3.6). We used a combination of PMA and
TNF- in most subsequent experiments.
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Figure 3.6. TNF- does not substantially alter expression of non-A3A APOBECs. qRT-PCR
for mRNA expression of APOBEC3s relative to TBP in NOK cells treated with 25 ng/ml PMA
alone or in combination with 10 ng/ml TNF-α for 24 hours. Mean and SD are shown for
triplicate qRT-PCR reactions. * not detected
3.3.2 Protein expression and DNA-cytosine deamination activity following PMA treatment
The expression of A3A was readily seen in a Western blot following PMA treatment, but
not in the absence of treatment (Figure 3.7). The bands seen in this blot correspond to the sizes of
two known functional isoforms of A3A which differ from each other by 12 amino
acids(323,348). Consistent with the qRT-PCR data, there was further increase in the intensities
of both the A3A bands when TNF- was included with PMA during treatment (Figure 3.7).
Although the monoclonal antibody used here reacts with both A3A and A3B(187), no bands at
the size of full-length A3B were detected (Figure 3.7) suggesting that although the A3B gene is
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transcribed in NOK cells (Figures 3.2 and 3.6), post-transcriptional or post-translational
regulation prevents the accumulation of A3B protein in cells.

Figure 3.7. PMA treatment increase expression of APOBEC3A protein but not
APOBEC3B. Western blot analysis of whole cell extracts of NOK cells which were untreated
(0) or treated with PMA or PMA and TNF-α for 24 hours. The primary antibody recognizes both
A3A and A3B. Expression level of β-actin was used as a control.
The presence of DNA-cytosine deaminase activity in NOK cells was tested using a 40mer containing a single cytosine and the resulting uracils were excised using E. coli Ung creating
a 25 nt product (Figure 3.8). Very small amounts of deamination activity was seen in untreated
cells, and it increased greater than ten-fold in both nuclear and cytoplasmic fractions of PMA
treated cells (Figure 3.8). Furthermore, the nuclear and cytoplasmic deamination activities were
higher following PMA+TNF- treatment compared with PMA alone (Figure 3.8). Together,
these results show that the treatment of NOK cells with PMA or PMA+TNF- increases
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transcription of both A3A and A3B genes, but the observed increases in DNA-cytosine
deamination activity are principally due to the A3A protein.

Figure 3.8. Expressed APOBEC3A protein is catalytically active. In vitro cytosine
deamination assay for nuclear and cytoplasmic fractions of treated NOK cells. Percentage of
product formation was calculated after quantifying the intensity of the bands (top: substrate,
bottom: product) and are shown below each lane.
3.3.3 Nuclear localization of APOBEC3A
Although, the appearance of nuclear deaminase activity following PMA and PMA+TNF treatment (Figure 3.8) was indicative of the presence of A3A in the nuclei, we were concerned
that the cytoplasmic fraction may have contaminated the nuclei during their preparation.
Furthermore, some previous work with monocytes has argued that A3A is found exclusively in
the cytoplasm(196). To detect the presence of A3A in the nuclei the stimulated NOK cells were
fixed, treated with anti-A3A/A3B antibody and visualized using fluorescence microscopy. The
microscope images showed an increase in A3A/A3B signal following PMA and TNF-
treatments and the protein(s) appeared as foci within the nuclei and cytoplasm (Figure 3.9). As
A3B is undetectable in Western blots, it is reasonable to assume that the new foci are due to
A3A.
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Figure 3.9. Immunofluorescence analysis of NOK cells for sub-cellular localization of
APOBEC3A. (A) Representative fluorescent microscopy images of untreated or treated NOK
cells stained for Cy3/A3A (red) and nuclei (green). (B) Quantification of nuclear fluorescence
intensity. The total number of cells used for quantification- None, 87; PMA-treated, 75; PMA+
TNF-α treated, 94. Mean intensity and SD for each type is shown.
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To further establish the nuclear localization of A3A, Z-sections were performed on the
images of stained cells using a confocal microscope. A Z-stack through the middle of a group of
cells showed that A3A/A3B foci were found within both the nucleus and cytoplasm of cells and
visualization of X-Z and Y-Z planes showed that several of the A3A foci resided within the
nucleus (Figure 3.10A). Furthermore, quantification of DAPI and fluorescence signals across one
cell showed that both the signals peaked over the nucleus (Figure 3.10B). This confirms the
results of cytosine deamination assays and clearly shows that some of the A3A/A3B protein,
presumably A3A, is present within the NOK nuclei.

A

B

Figure 3.10. Confocal microscopy analysis of NOK cells for sub-cellular localization of
APOBEC3A. (A) Confocal microscopy Z-stacking images of NOK cells treated with PMA and
TNF-α and immunostained for A3A (red) and nuclei (green). Orthogonal analysis of a foci in the
nucleus in X-Z and Y-Z planes shows overlap of red and blue. (B) Fluorescence intensity profile
across a cell in the confocal image.
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3.3.4 Lack of increase in genomic uracils in PMA and TNF- treated NOK cells
As PMA+TNF- treatment resulted in increased synthesis of A3A protein and its
transport into NOK nuclei, we determined whether this caused damage to DNA. We recently
described assays to quantify genomic uracils using alkoxyamines ARP and AA3(107,351). These
chemicals react with the abasic sites created by the excision of uracils in DNA by the uracilDNA

glycosylase

(UNG)

and

are

then

tagged

with

a

fluorescent

label

for

quantification(107,351). More recently, we also described another alkoxyamine, AA6, which
also reacts with abasic sites and can be attached with a fluorescent tag using non-copper-based
click chemistry(350). This method was developed by Lakshani Perera (Bhagwat lab) and is
shown in Figure 3.11.

A
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Figure 3.11. Quantification of uracils in genomic DNA using an alkoxyamine AA6.
(A) Reaction of AA6 with an basic site followed by DBCO-Cy5 reaction with AA6-AP adduct.
(B) Outline of the AA6 based uracil quantification assay.
When this method was used to quantify genomic uracils in cells treated with PMA or the
PMA+TNF-, little increase in the uracil levels was detected. While there was a decrease in
genomic uracils following the phorbol ester treatment in one experiment (Figure 3.12, set 1),
there was a slight increase in uracils in the second experiment (Figure 3.12, set 2).
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p <0.0001
p = 0.0003

Figure 3.12. Genomic uracil level in PMA treated NOK cells. Quantification of genomic
uracils in untreated, PMA or PMA and TNF-α treated NOK cells after 24 hours. 1 and 2 are two
independent experiments. Error bars represent SD across 4 technical replicates. P value was
calculated only for set 2, which shows a slight increase in uracils.
We previously showed that when murine splenocytes are stimulated ex vivo the
transcription of both AID and UNG genes is upregulated resulting in no net increase in genomic
uracil levels(107). Therefore, the unexpected lack of increase in uracil levels raised the
possibility that PMA causes an increase in uracil-excision activity by upregulating UNG and the
resulting higher enzyme levels are able to eliminate any excess uracils created by A3A. When
this possibility was tested by quantifying of UNG2 transcript using qRT-PCR, it was found that
24 hr following PMA and TNF- treatments, the expression of UNG gene decreased instead of
increasing (Figure 3.13A). Consequently, up-regulation of UNG gene is not the cause of the lack
of uracil level increase following PMA treatment. However, there was high level of UGIsensitive uracil excision activity in cells following PMA and PMA+TNF- treatment (Figure
3.13B).
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Figure 3.13. UNG2 expression and uracil excision activity in NOK cells following PMA and
PMA+TNF- treatment. (A) qRT-PCR for mRNA expression of UNG2 (nuclear isoform)
relative to TBP in treated NOK cells. (B) A fluorescently labeled DNA oligomer containing a
single uracil was used to determine the uracil excision activity in the whole cell extracts of
treated NOK cells in the presence or absence of the UNG enzyme inhibitor UGI. Percentage of
product formation was calculated after quantifying the intensity of the bands (top: substrate,
bottom: product) and are shown below each lane.
This raised the possibility that the endogenous UNG2 activity in NOK cells was so high
that it was able to eliminate uracils created by A3A even after PMA treatment reduced UNG2
expression. To test this, NOK cells were transfected with a plasmid expressing A3A from a
CMV promoter or a control plasmid lacking the A3A gene, and quantified the genomic uracils.
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We found that at both 24 hr and 48 hr following transfection there was significant increase in
genomic uracils (P-value < 0.001; Figure 3.14) showing that A3A expressed in NOK cells was
capable of deaminating cytosines in the genome creating an excess of uracils.

Figure 3.14. Genomic uracil level in APOBEC3A transfected NOK cells. Quantification of
genomic uracils in NOK cells transfected with a plasmid expressing A3A or control plasmid
lacking A3A gene (vector). Uracil levels in A3A transfected cells harvested at 24 hrs or 48 hrs
are shown. Error bars represent SD across 4 technical replicates.
3.3.5 Lack of increase in genomic uracils in PMA and TNF- treated UNG/ NOK cells
To determine further whether UNG2 in NOK cells was eliminating uracils created by
A3A following PMA and TNF- treatment, we constructed an UNG/ derivative of NOK cells
using CRISPR/Cas9 technology(352). The strategy involved deleting all of exon 3 and parts of
exons 2 and 4 which eliminates several residues critical for catalysis, and is outlined in Figure
3.15.
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Figure 3.15. Outline for the generation of UNG/ NOK cell line using CRISPR/Cas9
technology. Part of the human UNG gene is represented with gRNAs designed to target exon 2
and exon 4 causing a large deletion. Region of exon 4 coding for catalytically important residues
of UNG is shown as a vertical red line. Step by step approach for UNG knock out cell line
generation is illustrated. Green color cells are the NOK cells expressing GFP. The red dots inside
the cells indicate any mutation in UNG gene.
The resulting cells showed elimination of UNG-specific transcripts (Figure 3.16A),
complete loss of both UNG1 and UNG2 isoforms of the protein (Figure 3.16B) and a 90% loss in
uracil excision activity (Figure 3.16C). The remaining uracil excision activity is likely due to
back-up DNA glycosylases such as SMUG1(353-355).
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Figure 3.16. Validation of UNG/ NOK cell line. (A) qRT-PCR for mRNA expression of
UNG in wild type (WT) and UNG/ NOK cells relative to TBP. * not detected (B) Western blot
analysis of whole cell extracts for the expression of 2 isoforms of UNG protein. Expression level
of α-tubulin was used as a control. (C) Normalized uracil excision activity of UNG/ NOK cells
relative to WT (set to 100).
UNG/ NOK cells are still responsive to PMA and TNF- treatment overexpressing
A3A and increasing cytosine deamination activity in nuclear and cytoplasmic fractions (Figure
3.17).

A

B

105

C

Figure 3.17. UNG/ NOK cells are responsive to PMA and TNF- treatment. UNG/ NOK
cells were treated with PMA and PMA+TNF-α for 24 hours. (A) qRT-PCR for mRNA
expression of A3A relative to TBP. (B) Immunoblot for A3A, A3B and actin protein expression
levels in whole cell extracts. (C) DNA cytosine deamination activity in nuclear and cytoplasmic
fractions. Percentage of product formation was calculated after quantifying the intensity of the
bands (top: substrate, bottom: product).
Two independent clones of UNG/ cells that were characterized further had respectively
69% and 94% higher genomic uracils than WT NOK cells in the absence of PMA treatment
(Figure 3.18A). This suggests that the backup DNA repair pathways are unable to remove uracils
introduced in cellular DNA through spontaneous or A3B/A3C-mediated (Figure 3.2)
deamination of cytosines or the use of dUTP during replication (353,356) . However, treatment
of these cells with PMA or PMA+TNF- did not further increase the uracil levels, but instead
slightly decreased them (Figure 3.18A). As the expression of A3A peaks around 12 hr following
PMA treatment (Figure 3.4B), we determined the uracil levels at multiple time points during the
first 24 hr following PMA treatment, and found no increase in uracils at any of the points (Figure
3.18B). This is in contrast with the expression of A3A from a transfected plasmid, which doubles
the uracil levels after 48 hr in WT NOK cells (Figure 3.14) or increase after 24 hr in UNG/
cells (Figure 3.18C) . These data together with the uracil quantification data with WT NOK cells
(Figure 3.12) suggest that the phorbol ester treatment does not generate excess uracils through
endogenously expressed A3A protein and may, instead, result in fewer uracils in the genome.
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Figure 3.18. Quantification of genomic uracils in UNG/ NOK cells. (A) Uracils in untreated
WT cells and UNG/ NOK cells which were untreated, PMA or PMA and TNF-α treated for 24
hours. 1 and 2 are two independent knockout clones. (B) Quantification of genomic uracil levels
at different times after PMA and TNF-α treatment. (C) Uracils in UNG/ NOK cells transfected
with A3A expressing plasmid or empty vector for 24 hours. Error bars represent SD across 4
technical replicates.
3.3.6 PMA treatment causes reversible arrest in cell growth
We and others have shown that a major target for the APOBEC3 subfamily of enzymes
in the genome is the lagging strand template within replication forks(278,279,281,282). Based on
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this observation, we reasoned that the lack of increase in genomic uracils following phorbol ester
treatment could be explained if this treatment were to reduce replication. To test this, we
monitored the growth of NOK cells following PMA and TNF- treatments.

A

B

Figure 3.19. Effects of PMA treatment or A3A transfection on NOK cells growth and
viability. Comparison of change in (A) total cell number and (B) viability over 72 hours in NOK
cells which were untreated, treated with PMA or PMA and TNF-α and transfected with a
plasmid expressing A3A. Error bars represent SD from 6 biological replicates.
The treatment of cells with PMA alone stopped cell growth for at least 24 hr and this was
followed by a slow growth resulting an increase in cell number of only ~70% over three days.
The treatment with PMA+TNF- had even stronger effect on cell growth causing its complete
cessation for at least 72 hr (Figure 3.19A). This was in contrast with untreated cells which
increased five-fold in number and cells transfected with a plasmid expressing A3A tripled in
number during the same time period (Figure 3.19A). These data show that although both PMA
treatment and plasmid transfection result in increased A3A expression, the former treatment has
a much stronger negative effect on cell growth.
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The two experimental conditions also had different effects on cell viability. While the
PMA or PMA+TNF- had little effect on the viability of cells even after 72 hr treatment, the
cells transfected with plasmid expressing A3A lost viability after 24 hr decreasing it by about
20% over 72 hr (Figure 3.19B). Similarly, transfection of UNG∆/∆ NOK cells with A3A
expressing plasmid also showed a loss of viability, but little loss of viability when the same cells
were treated with PMA or PMA+TNF- (Figure 3.20).

A

B

Figure 3.20. Effects of PMA treatment or A3A transfection on UNG/ NOK cells growth
and viability. Comparison of change in (A) total cell number and (B) viability over 72 hours in
NOK cells which were untreated, treated with PMA or PMA and TNF-α and transfected with a
plasmid expressing A3A. Error bars represent SD from 6 biological replicates.
To confirm that the PMA+TNF- treated cells were indeed viable, we replaced the
growth medium in the treated and untreated cells every 24 hr and found that the cell density
increased gradually reaching the same density as untreated cells after 6 days (Figure 3.21).
Together these results show that PMA treatment of NOK cells stops cell growth (Figure 3.19A)
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without a loss of cell viability (Figure 3.19B), and does not result in the accumulation of uracils
in the genome (Figure 3.12). In contrast, NOK cells transfected with a plasmid expressing A3A
continue to grow after an initial pause (Figure 3.19A), accumulate uracils in their genome
(Figure 3.14) and lose viability (Figure 3.19B).

Figure 3.21. Growth arrest in NOK cells by PMA is reversible. Comparison of change in
total cell number of untreated or PMA and TNF-α treated NOK cells with daily media
replacement. Error bars represent SD from 6 biological replicates.
3.4 Discussion
The discovery of mutations caused by AID in immunoglobulin genes(15) and
APOBEC3G in the HIV genome(206) has raised the possibility that the AID/APOBEC family of
proteins could cause mutations in many cellular genes. Sequencing of individual genes(274),
whole exomes and genomes(266,269) in cells expressing these enzymes offer strong support for
this notion. In particular, the discovery that a substantial fraction of breast cancer cell lines(270)
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and patient tumors harbor elevated levels of A3B protein, genomic uracils, and mutations with a
signature characteristic of this deaminase suggested that these enzymes may make a major
contribution to cancer genome mutations(266,269,270). Subsequent demonstration that B cell
lymphoma cell lines and tumors also accumulate uracils and mutations characteristic of
AID(107,357), and other types of tumors contain certain mutations in sequence context preferred
by A3A/A3B(265,268,269,271,272), generally referred to as “APOBEC signature mutations”,
suggests that this is a general phenomenon in human cancer. As the causal relationship between
the expression of A3A/A3B genes with such mutations in human tumors is difficult to establish,
it is important to establish it in human tissue culture models. We have shown here that in contrast
to the results from many cancer genomes described above, the greatly elevated expression of
A3A and A3B genes in human keratinocytes does not correlate with increased damage to DNA
in the form of uracils. This suggests that the expression of these genes and their presence in
nuclei may not always lead to mutations and genome instability.
Our results were also unexpected because previous experiments in which A3A or A3B
genes were expressed from a CMV promoter in human cells via plasmid transfection, resulted in
mutations(243,270) and strand breaks(347). The expression of A3A from a plasmid-based TetOn system also resulted in the induction of DNA-damage response and cell cycle arrest in S
phase(277). We also found that expression of a plasmid-based A3A gene from a CMV promoter
in NOK cells results in increased levels of genomic uracils (Figure 3.14), confirming that the
expression of exogenously introduced A3A gene causes damage to the cellular genome.
A trivial explanation for the lack of increase in genomic uracils in UNG+/+ (Figure 3.12)
and UNG/ (Figure 3.18A) NOK cells following PMA or PMA+TNF- treatment is that the
expressed A3A is not transported into the nucleus or is efficiently exported out of it. In fact, A3A
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expressed in monocytes and macrophages following type I interferon treatment is predominantly
cytoplasmic in 2D images of cells stained with anti-A3A antibodies(358) and does not cause
mutations in the cellular thymidine kinase gene(195). We eliminated this possibility by
demonstrating that some A3A foci are seen in the nuclei of PMA treated NOK cells in both 2D
images and Z-sections across nuclei (Figures 3.9 and 3.10), and the nuclear cytosine deamination
activity increases following PMA treatment (Figure 3.8).
Consequently, the likely explanation for the lack of increase in genomic uracils following
the expression of PMA-induced A3A is that the substrate for the enzyme, ssDNA, is largely
absent in the treated cells. This happens because PMA treated NOK cells are severely inhibited
in cell growth (Figure 3.19). Depending on the cell type, PMA cause either cell cycle progression
or cell cycle arrest(359-365). When PMA causes cell cycle arrest, some cells arrest in
G2(359,362), while others arrest in G1 boundary(366) by a process referred to as hypermitogenic
arrest(367). In either case, the cells do not enter S phase.
In contrast, cells that have been transfected with A3A expressing plasmid continue to
divide after a 24 hour pause. We and others have shown that the APOBEC3 subfamily proteins,
when expressed in E. coli(282) or yeast(281) target the lagging strand template within replication
forks. Furthermore, analysis of human tumors with strong A3A/A3B mutational signatures have
shown that mutations are strand biased around replication origins in a manner that suggests that
the source of the mutations was cytosine deamination in the lagging strand template(278,279).
Furthermore, induction of chromosomal doxycycline-regulated A3A gene in a hepatic cell line
resulted in a significant increase in genomic uracils(277), which was dependent on the ability of
cells to enter S phase. Therefore, while A3A expressed through non-physiological means
(plasmid transfection or induction with doxycycline) introduces DNA damage in a replication-
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dependent manner, the lack of DNA replication in PMA treated NOK cells prevents the enzyme
from generating uracils at detectable levels.

Figure 3.22. Consequences of APOBEC3A expression in cancer cells and normal cells.
(A) In rapidly dividing cancer cells, A3A expression causes an increase in genomic uracils
resulting genome instability. (B) The outcomes of A3A expression in normal cells depend on the
mode of A3A induction and state of cell growth. The upper branch shows A3A localized
exclusively in the cytoplasm and preventing DNA damage. The middle branch shows A3A in
both cytoplasm and nucleus, and growth arrest protects the genome from A3A. The lower branch
shows results of non-physiological expression of A3A resulting in extensive DNA damage due
to continued DNA replication.
The AID/APOBEC family enzymes are potentially hazardous to the cell. They can cause
mutations, strand breaks and translocations(156,270,272,348) and have been implicated in
causing cancer(266,269,270,368) as well as in the diversification of tumors through mutations
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promoting drug resistance(342,343) (Figure 2.22A). Consequently, normal cells that express
these enzymes must have elaborate mechanisms to protect their genomes against them. One of
these mechanisms operates on A3F and A3G expressed in T cells and A3A expressed in
monocytes. In these cases, the proteins remain overwhelmingly in the cytoplasm(196,369,370)
and hence do not cause significant damage to the genome(196) (Figure 3.22B). In contrast with
these observations, we localized A3A to be in both cytoplasm and nucleus (Figures 3.9 and
3.10), but still found little evidence of genomic uracils (Figure 3.12). Another proposed
mechanism for protecting human genome against APOBECs is through proteins that bind the
deaminase. TRIB3 protein binds A3A and A3C causing the degradation of latter protein and
protecting the genome against cytosine deamination and strand breaks(346). This mechanism is
unlikely to be operative in NOK cells because we found robust levels of A3A protein and
cytosine deamination activity following stimulation with PMA.
The reversible cessation of DNA replication seen in NOK cells is an attractive
mechanism for protection against APOBEC enzymes. As these enzymes function to protect
against viruses and foreign DNA, their synthesis is likely to be upregulated in a cell in response
to cytokines released by neighboring infected cells. In this situation, the chances of cell survival
would be enhanced by the upregulation of APOBEC enzymes as part of a broad innate immune
response and the damage to the cellular genome would be minimized by a block in DNA
replication (Figure 3.22B). In contrast, tumor cells evolve to divide rapidly and hence the
overexpression of these proteins and their transport to the nucleus will result in mutations and
strand

breaks

in

the

cellular

genome.

This

should

lead

to

the

DNA

damage

response(277,347,371) and cell death through apoptosis(348). However, this could also lead to
genetic diversification of the tumor allowing it to adapt to its environment and escape anti-tumor
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chemotherapy(343). Therefore, the consequences of expression of APOBEC enzymes in
different cells are likely to be determined by a complex set of physiological responses involving
intracellular protein transport, protein degradation and cell growth.
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ABSTRACT
BIOCHEMICAL AND CELLULAR STUDIES OF APOBEC3 FAMILY
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Degree: Doctor of Philosophy
The AID/APOBEC family of enzymes deaminate cytosines in single-stranded DNA to
uracils leading to base substitutions and strand breaks. Members of APOBEC3 family in humans
are induced by cytokines produced during the body's inflammatory response to infections and
provide innate immunity against viruses. However, there is emerging consensus that these
enzymes can cause mutations in the cellular genome depending on the physiological state of the
cell and the phase of the cell cycle they are expressed. Since aberrant expression of APOBEC3B
was recently identified as a possible source of cancer, we initiated a study to determine the
maximally active catalytic domain of this enzyme. The results shed light on the structural
organization of APOBEC3B catalytic domain, its substrate specificity and its possible role in
causing genome-wide mutations. Next we determined the effects of inflammatory stimuli on
APOBEC3 expression and its consequences of genomic DNA by using a phorbol ester to induce
APOBEC3A expression in a keratinocyte cell line. The inability of APOBEC3A to cause uracil
accumulation in the genome was due to the reversible cessation of DNA replication and absence
of single-stranded DNA substrates. We identify the reversible arrest in cell growth as an
attractive mechanism to protect the human genome against APOBEC enzymes.
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